References Sections XI-XVI
International Council of Ophthalmology
Residency Curriculum 2011
References for each curriculum section have been updated in the 2011 Residency Curriculum. Evidence-based medicine, in which therapeutic decisions are based on documented, verifiable, and validated information, is an increasingly important educational framework upon which physicians should make recommendations for their patients. Whenever possible, updated references and sources of knowledge providing such information should receive precedence and preference by both teachers and students of clinical ophthalmology. Links to the practice of evidence-based medicine can be found at www.aao.org.
XI. Vitreoretinal
Diseases
Branch Vein Occlusion Studies (BVOS)
1. Branch Vein Occlusion Study Group. Argon laser scatter
photocoagulation for prevention of neovascularization and vitreous
hemorrhage in branch vein occlusion. A randomized clinical trial.
Branch Vein Occlusion Study Group. Arch Ophthalmol 1986; 104: 34-41.
2. The Branch Vein Occlusion Study Group. Argon laser
photocoagulation for macular edema in branch vein occlusion. The
Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98: 271-282.
3. Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental
cost-effectiveness of laser therapy for visual loss secondary to
branch retinal vein occlusion. Ophthalmic Epidemiol 2002; 9:1-10.
4. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC,
Murahashi WY, Rubio RG; BRAVO Investigators. Ranibizumab for
macular edema following branch retinal vein occlusion: six-month
primary end point results of a phase III study. Ophthalmology. 2010
Jun;117(6):1102-1112.
5. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N,
Adamis AP, Rubio RG, Murahashi WY. Sustained benefits from
Ranibizumab for macular edema following branch retinal vein
occlusion: 12-month outcomes of a phase III study. Ophthalmology.
2011 Jun 17. [Epub ahead of print]
Additional Background Reading
1. Barbazetto IA, Schmidt-Erfurth UM. Evaluation of functional
defects in branch retinal vein occlusion before and after laser
treatment with scanning laser perimetry. Ophthalmology 2000; 107:
1089 -1098.
2. Saxena S. Laser photocoagulation in retinal vein occlusion: branch
vein occlusion study and central vein occlusion study
recommendations. Indian J Ophthalmol 1997; 45: 125 -128. Comment:
1997;45:261 -262.
3. Cousins SW, Flynn HW Jr., Clarkson JG. Macroaneurysms associated
with retinal branch vein occlusion. Am J Ophthalmol 1990;109:567-570.
4. Finkelstein D. Argon laser photocoagulation for macular edema in
branch vein occlusion. Ophthalmology 1986; 93: 975 ¬977.
5. (No authors listed). Branch vein occlusion study. Invest
Ophthalmol Vis Sci 1979;18:1097.
Macular Photocoagulation Study (MPS)
1. Macular Photocoagulation Study Group. Risk factors for choroidal
neovascularization in the second eye of patients with juxtafoveal or
subfoveal choroidal neovascularization secondary to age-related
macular degeneration. Macular Photocoagulation Study Group. Arch
Ophthalmol 1997;115:741-747.
2. Macular Photocoagulation Study Group. Laser photocoagulation for
juxtafoveal choroidal neovascularization. Five-year results from
randomized clinical trials. Macular Photocoagulation Study Group.
Arch Ophthalmol 1994;112:500-509.
3. Macular Photocoagulation Study Group. Five-year follow-up of
fellow eyes of patients with age-related macular degeneration and
unilateral extrafoveal choroidal neovascularization. Macular
Photocoagulation Study Group. Arch Ophthalmol 1993;111:1189-1199.
4. Macular Photocoagulation Study Group. Laser photocoagulation of
subfoveal neovascular lesions of age-related macular degeneration.
Updated findings from two clinical trials. Macular Photocoagulation
Study Group. Arch Ophthalmol 1993;111:1200-1209.
5. Macular Photocoagulation Study Group. Argon laser photocoagulation
for neovascular maculopathy. Five-year results from randomized
clinical trials. Macular Photocoagulation Study Group. Arch
Ophthalmol1991;109:1109-1114.
6. Macular Photocoagulation Study Group. Krypton laser
photocoagulation for neovascular lesions of age-related macular
degeneration. Results of a randomized clinical trial. Macular
Photocoagulation Study Group. Arch Ophthalmol 1990;108:816-82.
7. Macular Photocoagulation Study Group. Persistent and recurrent
neovascularization after krypton laser photocoagulation for
neovascular lesions of age-related macular degeneration. Macular
Photo-coagulation Study Group. Arch Ophthalmol 1990;108:825-831.
8. Bressler SB, Maguire MG, Bressler NM, Fine SL. Relationship of
drusen and abnormalities of the retinal pigment epithelium to the
prognosis of neovascular macular degeneration. The Macular
Photocoagulation Study Group. Arch Ophthalmol 1990; 108: 1442 -1447.
9. Chamberlin JA, Bressler NM, Bressler SB et al. The use of fundus
photographs and fluorescein angiograms in the identification and
treatment of choroidal neovascularization in the Macular
Photocoagulation Study. The Macular Photocoagulation Study Group.
Ophthalmology 1989; 96: 1526 -1534.
10. Macular Photocoagulation Study Group. Krypton laser
photocoagulation for neovascular lesions of ocular histoplasmosis.
Results of a randomized clinical trial. Macular Photocoagulation
Study Group. Arch Ophthalmol 1987;105:1499-1507.
11. Macular Photocoagulation Study Group. Recurrent choroidal
neovascularization after argon laser photocoagulation for neovascular
maculopathy. Macular Photocoagulation Study Group. Arch Ophthalmol
1986;104:503-512.
12. Macular Photocoagulation Study Group. Argon laser
photocoagulation for neovascular maculopathy. Three-year results from
randomized clinical trials. Macular Photocoagulation Study Group.
Arch Ophthalmol 1986;104:694-701.
13. Macular Photocoagulation Study Group. Argon laser
photocoagulation for ocular histoplasmosis. Results of a randomized
clinical trial. Arch Ophthalmol 1983;101:1347-1357.
14. Macular Photocoagulation Study Group. Argon laser
photocoagulation for idiopathic neovascularization. Results of a
randomized clinical trial. Arch Ophthalmol 1983;101:1358-1361.
15. (No authors listed). Argon laser photocoagulation for senile
macular degeneration. Results of a randomized clinical trial. Arch
Ophthalmol 1982; 100: 912-918.
16. Zimmer-Galler IE, Bressler NM, Bressler SB. Treatment of
choroidal neovascularization: updated information from recent macular
photocoagulation study group reports. Int Ophthalmol Clin
1995;35:37-57.
Additional Background Reading
1. Macular Photocoagulation Study Group. Occult choroidal
neovascularization. Influence on visual outcome in patients with
age-related macular degeneration. Macular Photocoagulation Study
Group. Arch Ophthalmol 1996;114:400-412.
2. Macular Photocoagulation Study Group. Five-year follow-up of
fellow eyes of individuals with ocular histoplasmosis and unilateral
extrafoveal or juxtafoveal choroidal neovascularization. Macular
Photocoagulation Study Group. Arch Ophthalmol 1996;114: 677-688.
3. Macular Photocoagulation Study Group. Laser photocoagulation for
neovascular lesions nasal to the fovea. Results from clinical trials
for lesions secondary to ocular histoplasmosis or idiopathic causes.
Macular Photocoagulation Study Group. Arch Ophthalmol 1995;113:56-61.
4. Macular Photocoagulation Study Group. The influence of treatment
extent on the visual acuity of eyes treated with Krypton laser for
juxtafoveal choroidal neovascularization. Macular Photocoagulation
Study Group. Arch Ophthalmol 1995;113:190-194.
5. Macular Photocoagulation Study Group. Persistent and recurrent
neovascularization after laser photocoagulation for subfoveal
choroidal neovascularization of age-related macular degeneration.
Macular Photocoagulation Study Group. Arch Ophthalmol
1994;112:489-499.
6. Macular Photocoagulation Study Group. Evaluation of argon green vs
krypton red laser for photocoagulation of subfoveal choroidal
neovascularization in the macular photocoagulation study. Macular
Photocoagulation Study (MPS) Group. Arch Ophthalmol
1994;112:11761-1184.
7. Orr PR, Blackhurst DW, Hawkins BS. Patient and clinic factors
predictive of missed visits and inactive status in a multicenter
clinical trial. The Macular Photocoagulation Study Group. Control
Clin Trials 1992; 13:40-49.
8. Bressler NM, Bressler SB, Alexander J et al. Loculated fluid. A
previously undescribed fluorescein angiographic finding in choroidal
neovascularization associated with macular degeneration. Macular
Photocoagulation Study Reading Center. Arch Ophthalmol 1991;
109:211-215.
9. Macular Photocoagulation Study Group. Laser photocoagulation of
subfoveal neovascular lesions in age-related macular degeneration.
Results of a randomized clinical trial. Macular Photocoagulation
Study Group. Arch Ophthalmol 1991;109:1220 -1231.
10. Macular Photocoagulation Study Group. Laser photocoagulation of
subfoveal recurrent neovascular lesions in age-related macular
degeneration. Results of a randomized clinical trial. Macular
Photocoagulation Study Group. Arch Ophthalmol 1991;109:1232-1241.
11. Macular Photocoagulation Study Group. Subfoveal neovascular
lesions in age-related macular degeneration. Guidelines for
evaluation and treatment in the macular photocoagulation study.
Macular Photocoagulation Study Group. Arch Ophthalmol 1991;
109:1242-1257.
12. Hawkins BS, Prior MJ, Fisher MR, Blackhurst DW. Relationship
between rate of patient enrollment and quality of clinical center
performance in two multicenter trials in ophthalmology. Control Clin
Trials 1990;11:374-394.
13. Macular Photocoagulation Study Group. Krypton laser
photocoagulation for idiopathic neovascular lesions. Results of a
randomized clinical trial. Macular Photocoagulation Study Group. Arch
Ophthalmol 1990;108:832-837.
14. Blackhurst DW, Maguire MG. Reproducibility of refraction and
visual acuity measurement under a standard protocol. The Macular
Photocoagulation Study Group. Retina 1989;9:163-169.
15. Macular Photocoagulation Study Group. Persistent and recurrent
neovascularization after krypton laser photocoagulation for
neovascular lesions of ocular histoplasmosis. Macular
Photocoagulation Study Group. Arch Ophthalmol 1989;107:344-352.
16. Fine SL. Early detection of extrafoveal neovascular membranes by
daily central field evaluation. Ophthalmology 1985;92:603-609.
17. Macular Photocoagulation Study Group .Changing the protocol: a
case report from the Macular Photocoagulation Study. Macular
Photocoagulation Study Group. Control Clin Trials 1984;5:203-216.
18. Gottfredsdottir MS, Sverrisson T, Musch DC, Stefansson E. Age
related macular degeneration in monozygotic twins and their spouses
in Iceland. Acta Ophthalmol Scand 1999;77:422-425.
19. Macular Photocoagulation Study Group. Age-related macular
degeneration. The Macular Photocoagulation Study. Am J Ophthalmol
1984;98:376-377.
20. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular
degeneration and choroidal neovascularization. Am J Ophthalmol
1993;115:786-791.
21. Jampol LM. Hypertension and visual outcome in the macular
photocoagulation study. Arch Ophthalmol 1991;109:789-790.
22. Jost BF, Alexander MF, Maguire MG et al. Laser treatment for
choroidal neovascularization outside randomized clinical trials. Arch
Ophthalmol 1988;106:357-361.
23. Fine SL. Macular photocoagulation study. Arch Ophthalmol 1980;98:
832.
24. Fine SL, Hawkins B, Maguire M. Macular photocoagulation study.
Arch Ophthalmol 1984; 102:1583.
25. Jampol LM, Tielsch J. Race, macular degeneration, and the Macular
Photocoagulation Study. Arch Ophthalmol 1992; 110: 1699-1700.
26. Moisseiev J, Alhalel A, Masuri R, Treister G. The impact of the
macular photocoagulation study results on the treatment of exudative
age-related macular degeneration. Arch Ophthalmol 1995; 113: 185
-189.
27. Beatty S, Au Eong KG, McLeod D, Bishop PN. Photocoagulation of
subfoveal choroidal neovascular membranes in age related macular
degeneration: the impact of the macular photocoagulation study in the
United Kingdom and Republic of Ireland.Br J Ophthalmol 1999; 83:1103
-1104.
28. Custis PH, Bressler SB, Bressler NM. Laser management of
subfoveal choroidal neovascularization in age-related
maculardegeneration. Curr Opin Ophthalmol1993; 4: 7-18.
29. Dyer DS, Bressler SB, Bressler NM. The role of laser wavelength
in the treatment of vitreoretinal diseases. Curr Op in Ophthalmol
1994; 5: 35-43.
30. Bergink GJ, Deutman AF, van den Broek JF, van Daal WA, van der
Maazen RW. Radiation therapy for subfoveal choroidal neovascular
membranes in age-related macular degeneration. A pilot study. Graefes
Arch Clin Exp Ophthalmol 1994;232:591-598.
31. Gelfand YA, Linn S, Miller B. The application of the macular
photocoagulation study eligibility criteria for laser treatment in
age-related macular degeneration. Ophthalmic Surg Lasers
1997;28:823-827.
32. Spaide RF, Guyer DR, McCormick B et al. External beam radiation
therapy for choroidal neovascularization. Ophthalmology
1998;105:24-30
33. Ormerod LD, Puklin JE, Frank RN. Long-term outcomes after the
surgical removal of advanced subfoveal neovascular membranes in
age-related macular degeneration. Ophthalmology1994;101:1201-1210.
34. Avvad FK, Duker JS, Reichel E, Margolis TI, Puliafito CA. The
digital indocyanine green videoangiography characteristics of
well-defined choroidal neovascularization. Ophthalmology
1995;102:401-405.
35. Yannuzzi LA. A new standard of care for laser photocoagulation of
subfoveal choroidal neovascularization secondary to age-related
macular degeneration. Data revisited. Arch Ophthalmol 1994;112
462-464.
36. Tiedeman JS. Treatment of subfoveal choroidal neovascularization.
Arch Ophthalmol 1995; 113:137-138.
37. Hawkins WR. Visual prognosis of eyes with submacular choroidal
neovascularization. Arch Ophthalmol 1994; 112: 874 -875.
38. Fine SL, Hawkins BS, Maguire MG. Krypton Laser photocoagulation
for neovascular lesions of age-related macular degeneration. Arch
Ophthalmol 1991; 109: 614-615.
39. Tornambe PE, Poliner LS. Partial ablation of neovascular
membranes involving the fovea. Arch Ophthalmol 1989;107: 955-956.
40. Wolfe JA, Horton MB, McAteer MB, Szuter CF, Clayton T. Race,
macular degeneration, and diabetic maculopathy. Arch Ophthalmol 1993;
111: 1603 -1604.
41. Chakravarthy U, Hart P, Finger P. External beam radiation therapy
for CNV. Ophthalmology 1998; 105:1790-1791; author reply 1791 -1792
Beaumont P, Chang A. External beam radiation therapy for CNV.
Ophthalmology 1998; 105: 1792 -1793; author reply 1793 -1794.
42. Schachat AP. Management of subfoveal choroidal
neovascularization. Arch Ophthalmol 1991; 109:1217-1218.
Age-Related Eye Disease Study (AREDS)
1. Clemons TE, Chew EY, Bressler SB, McBee W. National Eye Institute
Visual Function questionnaire in the Age-Related Eye Disease Study
(AREDS): AREDS Report No. 10. Arch Ophthalmol 2003; 121: 211-217.
2. Age-Related Eye Disease Study Research Group. The effect of
five-year zinc supplementation on serum zinc, serum cholesterol and
hematocrit in persons randomly assigned to treatment group in the
age-related eye disease study: AREDS Report No. 7.J Nutr 2002; 132:
697-702.
3. Age-Related Eye Disease Study Research Group. A randomized,
placebo-controlled, clinical trial of high-dose supplementation with
vitamins C and E and beta carotene for age-related cataract and
vision loss: AREDS report no. 9. Arch Ophthalmol 2001; 119:
1439-1452.
4. Age-Related Eye Disease Study Research Group. A randomized,
placebo-controlled, clinical trial of high-dose supplementation with
vitamins C and E, beta carotene, and zinc for age-related macular
degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol
2001; 119: 1417-1436.
5. Age-Related Eye Disease Study Research Group. The Age-Related Eye
Disease Study system for classifying age-related macular degeneration
from stereoscopic color fundus photographs: the Age-Related Eye
Disease Study Report Number 6. Am J Ophthalmol 2001; 132: 668-681.
6. Age-Related Eye Disease Study Research Group. The age-related eye
disease study (AREDS) system for classifying cataracts from
photographs: AREDS report no. 4. Am J Ophthalmol 2001; 131: 167-175.
7. (No authors listed). Risk factors associated with age-related
nuclear and cortical cataract: a case-control study in the
Age-Related Eye Disease Study, AREDS Report No. 5. Ophthalmology
2001; 108:1400-1408.
8. (No authors listed). The Age-Related Eye Disease Study: a clinical
trial of zinc and antioxidants -Age-Related Eye Disease Study Report
No. 2. J Nutr 2000; 130: 1516S -1519S.
9. (No authors listed). Risk factors associated with age-related
macular degeneration. A case-control study in the age-related eye
disease study: Age-Related Eye Disease Study Report Number 3.
Ophthalmology 2000; 107: 2224-2232.
10. (No authors listed). The Age-Related Eye Disease Study (AREDS):
design implications. AREDS report no. 1. Control Clin Trials 1999;
20: 573-600.
AMD Studies
1. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR;
MARINA Study Group. Improved vision-related function after
ranibizumab treatment of neovascular age-related macular
degeneration: results of a randomized clinical trial. Arch
Ophthalmol. 2007 Nov;125(11):1460-9.
2. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H,
Schneider S, Acharya NR. Ranibizumab for predominantly classic
neovascular age-related macular degeneration: subgroup analysis of
first-year ANCHOR results. Am J Ophthalmol. 2007 Dec;144(6):850-857.
3. Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J,
Ianchulev T; MARINA and ANCHOR Research Groups. Vision-related
function after ranibizumab treatment by better- or worse-seeing eye:
clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010
Apr;117(4):747-56.
4. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B;
MARINA and ANCHOR Study Groups. Characteristics of patients losing
vision after 2 years of monthly dosing in the phase III ranibizumab
clinical trials. Ophthalmology. 2011 Mar;118(3):523-30.
5. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE,
Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular
age-related macular degeneration. N Engl J Med. 2011 May
19;364(20):1897-908.
6. Martin DF, Maguire MG,
Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL
3rd; Comparison of Age-related Macular Degeneration Treatments
Trials (CATT) ResearchGroup Writing Committee. Ranibizumab
and Bevacizumab for Treatment of Neovascular Age-Related Macular
Degeneration: Two-Year Results. Ophthalmology. 2012
May 1. [Epub ahead of print].
Vertoporfin in Photodynamic Therapy (VIP)
1. Blinder KJ, Blumenkranz MS, Bressler NM et al. Verteporfin therapy
of subfoveal choroidal neovascularization in pathologic myopia:
2-year results of a randomized clinical trial –VIP report no.3.
Ophthalmology 2003; 110:667-673.
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin
therapy of subfoveal choroidal neovascularization in age-related
macular degeneration: two-year results of a randomized clinical trial
including lesions with occult with no classic choroidal
neovascularization -verteporfin in photo-dynamic therapy report 2. Am
J Ophthalmol 2001; 131: 541-560.
3. Verteporfin in Photodynamic Therapy Study Group. Photodynamic
therapy of subfoveal choroidal neovascularization in pathologic
myopia with verteporfin. 1-year results of a randomized clinical
trial -VIP report no. 1. Ophthalmology 2001; 108: 841-852.
4. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of
age-related macular degeneration with photodynamic therapy (TAP)
study group principal investigators, Verteporfin in photodynamic
therapy (VIP) study group principal investigators. Guidelines for
using verteporfin (visudyne) in photodynamic therapy to treat
choroidal neovascularization due to age-related macular degeneration
and othercauses. Retina 2002; 22:6-18.
Treatment of Age-Related Macular Degeneration with Photodynamic
Therapy (TAP)
1. Blumenkranz MS, Bressler NM, Bressler SB et al. Verteporfin
therapy for subfoveal choroidal neovascularization in age-related
macular degeneration: three-year results of an open-label extension
of 2 randomized clinical trials -TAP Report no. 5. Arch Ophthalmol
2002; 120: 1307-1314.
2. Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast
on sensitivity: Results From the Treatment of Age-Related Macular
Degeneration With Photodynamic Therapy (TAP) investigation-TAP report
No 4. Retina 2002; 22: 536¬544.
3. Bressler NM, Arnold J, Benchaboune M et al. Verteporfin therapy of
subfoveal choroidal neovascularization in patients with age-related
macular degeneration: additional information regarding baseline
lesion composition's impact on vision outcomes-TAP report No. 3. Arch
Ophthalmol 2002; 120: 1443-1454.
4. Bressler NM. Photodynamic therapy of subfoveal choroidal
neovascularization in age-related macular degeneration with
verteporfin: two-year results of 2 randomized clinical trials-tap
report 2. Arch Ophthalmol 2001; 119: 198-207.
5. Miller JW, Schmidt-Erfurth U, Sickenberg M et al. Photodynamic
therapy with verteporfin for choroidal neovascularization caused by
age-related macular degeneration: results of a single treatment in a
phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1161-1173 [Erratumin:
Arch Ophthalmol 2000 Apr; 1118: 1488].
6. (No authors listed). Photodynamic therapy of subfoveal choroidal
neovascularization in age-related macular degeneration with
verteporfin: one-year results of 2 randomized clinical trials -TAP
report. Treatment of age-related macular degeneration with
photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;
117:1329-1345 [Erratum in: Arch Ophthalmol 2000 April; 1118: 1488].
Silicone Study
1. Abrams GW, Azen SP, McCuen BW, 2nd et al. Vitrectomy with silicone
oil or long-acting gas in eyes with severe proliferative
vitreoretinopathy: results of additional and long-term follow-up.
Silicone Study report 11. Arch Ophthalmol 1997; 115: 335-344.
2. McCuen BW, 2nd, Azen SP, Stern W et al. Vitrectomy with silicone
oil or perfluoropropane gas in eyes with severe proliferative
vitreoretinopathy. Silicone Study Report 3. Retina 1993; 13: 279
-284.
3. (No authors listed). Vitrectomy with silicone oil or sulfur
hexafluoride gas in eyes with severe proliferative vitreoretinopathy:
results of a randomized clinical trial. Silicone Study Report 1. Arch
Ophthalmol 1992; 110:770-779.
4. (No authors listed). Krypton laser photocoagulation for
neovascular lesions of ocular histoplasmosis. Results of a randomized
clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol
1987; 105: 1499-1507.
5. (No authors listed). Vitrectomy with silicone oil or
perfluoropropane gas in eyes with severe proliferative
vitreoretinopathy: results of a randomized clinical trial. Silicone
Study Report 2. Arch Ophthalmol 1992; 110: 780 -792.
6. Lean JS, Stern WH, Irvine AR, Azen SP. Classification of
proliferative vitreoretinopathy used in the silicone study. The
Silicone Study Group. Ophthalmology 1989; 96: 765-771.
7. Brown GC, Brown MM, Sharma S, Busbee B, Landy J. A cost-utility
analysis of interventions for severe proliferative vitreoretinopathy.
Am J Ophthalmol 2002; 133:365-372.
8. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv
Ophthalmol 1998; 43:3 -18.
Additional Background Reading
1. Diddie KR, Azen SP, Freeman HM et al. Anterior proliferative
vitreoretinopathy in the silicone study. Silicone Study Report
Number10. Ophthalmology1996; 103:1092 -1099 Lean J, Azen SP, Lopez PF
et al. The prognostic utility of the Silicone Study Classification
System. Silicone Study Report 9. Silicone Study Group . Arch
Ophthalmol 1996; 114:286-292.
2. Abrams GW, Azen SP, Barr CC et al. The incidence of corneal
abnormalities in the Silicone Study. Silicone Study Report 7. Arch
Ophthalmol 1995; 113: 764-769.
3. Cox MS, Azen SP, Barr CC et al. Macular pucker after successful
surgery for proliferative vitreoretinopathy. Silicone Study Report 8.
Ophthalmology 1995; 102: 1884-1891.
4. Hutton WL, Azen SP, Blumenkranz MS et al. The effects of silicone
oil removal. Silicone Study Report 6. Arch Ophthalmol 1994; 112:
778-785.
5. Peyman GA, Greve MD, Millsap CM. Silicone oil vs perfluoropropane
gas as a postoperative retinal tamponade. Arch Ophthalmol 1994; 112:
728 -729; Reply by McCuen BW, Azen SP: 729.
6. Chan CK. Reports by the Silicone Study Group. Arch Ophthalmol
1993; 111: 428; author reply 429 Le Mer Y. Reports by the Silicone
Study Group. Arch Ophthalmol 1993; 111: 429.
7. Barr CC, Lai MY, Lean JS et al. Postoperative intraocular pressure
abnormalities in the Silicone Study. Silicone Study Report 4.
Ophthalmology 1993; 100: 1629 -1635.
8. Blumenkranz MS, Azen SP, Aaberg T et al. Relaxing retinotomy with
silicone oil or long-acting gas in eyes with severe proliferative
vitreoretinopathy. Silicone Study Report 5. The Silicone Study Group.
Am J Ophthalmol 1993; 116: 557-564.
9. Azen SP, Boone DC, Barlow W et al. Methods, statistical features,
and baseline results of a standardized, multicentered ophthalmologic
surgical trial: the Silicone Study. Control Clin Trials 1991; 12:
438-455.
10. Barlow W, Azen S. The effect of therapeutic treatment crossovers
on the power of clinical trials. The Silicone Study Group. Control
Clin Trials 1990; 11: 314 -326
11. Azen SP, Irvine AR, Davis MD et al. The validity and reliability
of photographic documentation of proliferative vitreoretinopathy.
Ophthalmology 1989; 96:352-357.
12. Boone DC, Lai M, Azen S, Silicone Study Group. Clinical judgment
and centralized data management. Control Clin Trials 1989: 339.
13. Irvine AR. Photographic documentation and grading of PVR, in
Freeman HM, Tolentino FI (eds). Proliferative Vitreoretinopathy, New
York, Springer-Verlag 1989: 105-109.
14. Stern WH, Lean JS, Silicone Study Group. Intraocular silicone oil
versus gas in the management of proliferative vitreoretinopathy
(PVR): A multicenter clinical study, in Freeman HM, Tolentino FI
(eds). Proliferative Vitreoretinopathy. New York, Springer-Verlag,
1989.
15. Glaser BM. Silicone oil for proliferative vitreoretinopathy. Does
it help or hinder? Arch Ophthalmol 1988; 106:323-324.
16. Lean JS. Changing attitudes in United States to use of
intravitreal silicone. Jpn J Ophthalmol 1987; 31: 132-137.
17. (No authors listed). Proliferative vitreoretinopathy (editorial).
The Silicone Study Group. Am J Ophthalmol 1985; 99: 593-595.
18. Campochiaro PA. The Silicone Study. A small piece of the PVR
puzzle is put into place. Arch Ophthalmol 1997; 115: 407-408.
19. Haller JA, Campochiaro PA. Oil and gas on troubled waters. The
proliferative vitreoretinopathy studies. Arch Ophthalmol 1992; 110:
768 -769.
Submacular Surgery Trials (SST)
1. Bressler NM, Hawkins BS, Sternberg P Jr., McDonald HR. Are the
submacular surgery trials still relevant in an era of photo dynamic
therapy? Ophthalmology 2001; 108: 435-436.
2. Grossniklaus HE, Green WR. Histopathologic and ultrastructural
findings of surgically excised choroidal neovascularization.
Submacular Surgery Trials Research Group. Arch Ophthalmol 1998; 116:
745-749.
Additional Background Reading
1. Bressler NM, Bressler SB, Hawkins BS et al. Submacular surgery
trials randomized pilot trial of laser photocoagulation versus
surgery for recurrent choroidal neovascularization secondary to
age-related macular degeneration: I. Ophthalmic outcomes submacular
surgery trials pilot study report number 1. Am J Ophthalmol 2000;
130: 387-407.
2. photocoagulation versus surgery for recurrent choroidal
neovascularization secondary to age-related macular degeneration: II.
Quality of life outcomes submacular surgery trials pilot study report
number 2. Am J Ophthalmol 2000; 130: 408 -418.
3. Bressler NM. Submacular surgery. New information, more questions.
Arch Ophthalmol 1997;115:1071-1072.
4. Bressler NM. Submacular surgery. Are randomized trials necessary?
Arch Ophthalmol 1995;113:1557-1560.
5. Dong LM, Hawkins BS, Marsh MJ. Consistency between visual acuity
scores obtained at different test distances: theory vs observations
in multiple studies. Arch Ophthalmol 2002; 120:1523-1533.
6. Orr PR, Cramer LD, Hawkins BS, Bressler NM. Manifest refraction
versus autorefraction for patients with subfoveal choroidal
neovascularization. Invest Ophthalmol Vis Sci 2001;42:447-452.
7. Fleckner MR, Hochman MA, Buzney SM et al. Complications of surgery
for subfoveal choroidal neovascularization. Int Ophthalmol Clin
2000;40:201-214.
8. Uemura A. [Subretinal surgery for choroidal neovascularization].
Nippon Ganka Gakkai Zasshi 2000;104:611-620.
9. Rao PK, Thomas MA. Update on surgical removal of choroidal
neovascularization. Curr Op in Ophthalmol 2000;11:180-185.
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity
(CRYO-ROP)
1. (No authors listed). Multicenter Trial of Cryotherapy for
Retinopathy of Prematurity: ophthalmological outcomes at 10 years.
Arch Ophthalmol 2001; 119: 1110 -1118.
2. Repka M., Palmer EA, Tung B. Involution of retinopathy of
prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative
Group. Arch Ophthalmol 2000; 118:645-649.
3. Saunders RA, Donahue ML, Christmann LM et al. Racial variation in
retinopathy of prematurity. The Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Arch Ophthalmol 1997; 115: 604-608.
4. Bartholomew PA, Chao J, Evans JL et al. Acceptance/Use of the
Teller acuity card procedure in the clinic. Am Orthoptic J 1996; 46:
100-106.
5. Quinn GE, Dobson V, Barr CC et al. Visual acuity of eyes after
vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years.
The Cryotherapy for Retinopathy of Prematurity Cooperative Group.
Ophthalmology 1996; 103: 595-600.
6. (No authors listed). Multicenter trial of cryotherapy for
retinopathy of prematurity: natural history ROP: ocular outcome at
5(1/2) years in premature infants with birth weights less than 1251
g. Arch Ophthalmol 2002; 120: 595-599.
7. Dobson V, Quinn GE, Summers CG, Hardy RJ, Tung B; Cryotherapy for
Retinopathy of Prematurity Cooperative Group. Visual acuity at 10
years in Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) study
eyes: effect of retinal residua of retinopathy of prematurity. Arch
Ophthalmol. 2006 Feb;124(2):199-202.
8. Msall ME, Phelps DL, Hardy RJ, Dobson V, Quinn GE, Summers CG,
Tremont MR; Cryotherapy for Retinopathy of Prematurity Cooperative
Group. Educational and social competencies at 8 years in children
with threshold retinopathy of prematurity in the CRYO-ROP multicenter
study. Pediatrics. 2004 Apr;113(4):790-9.
Additional Background Reading
1. (No authors listed). Contrast sensitivity at age 10 years in
children who had threshold retinopathy of prematurity. Arch
Ophthalmol 2001; 119: 1129 -1133.
2. (No authors listed). Effect of retinal ablative therapy for
threshold retinopathy of prematurity: results of Goldmann perimetry
at the age of 10 years. Arch Ophthalmol 2001; 119: 1120 -1125.
3. Quinn GE, Dobson V, Siatkowski R et al. Does cryotherapy affect
refractive error? Results from treated versus control eyes in the
cryotherapy for retinopathy of prematurity trial. Ophthalmology 2001;
108: 343 -347.
4. Msall ME, Phelps DL, DiGaudio KM et al. Severity of neonatal
retinopathy of prematurity is predictive of neurodevelopmental
functional outcome at age 5.5 years. Behalf of the Cryotherapy for
Retinopathy of Prematurity Cooperative Group. Pediatrics 2000; 106:
998 -1005.
5. Dobson V, Quinn GE, Siatkowski RM et al. Agreement between grating
acuity at age 1 year and Snellen acuity at age 5.5 years in the
preterm child. Cryotherapy for Retinopathy of Prematurity Cooperative
Group. Invest Ophthalmol Vis Sci 1999;40: 496 -503.
6. Harvey EM, Dobson V, Tung B, Quinn GE, Hardy RJ. Interobserver
agreement for grating acuity and letter acuity assess¬ment in 1-to
5.5-year-olds with severe retinopathy of prematurity. Invest
Ophthalmol Vis Sci 1999; 40: 1565 -1576.
7. GE, Dobson V, Kivlin J et al. Prevalence of myopia between 3
months and 5 1/2 years in preterm infants with and without
retinopathy of prematurity. Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Ophthalmology 1998; 105: 1292 -1300.
8. Bremer DL, Palmer EA, Fellows RR et al. Strabismus in premature
infants in the first year of life. Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Arch Ophthalmol 1998; 116: 329-333.
9. Repka M, Summers CG, Palmer EA et al. The incidence of
ophthalmologic interventions in children with birth weights less than
1251 grams. Results through 5 1/2 years. Cryotherapy for Retinopathy
of Prematurity Cooperative Group. Ophthalmology 1998; 105: 1621
-1627.
10. Hardy RJ, Palmer EA, Schaffer DB et al. Outcome-based management
of retinopathy of prematurity. Multicenter Trial of Cryotherapy for
Retinopathy of prematurity Cooperative Group.JAapos1997; 1:46-54.
11. (No authors listed). Multicenter trial of cryotherapy for
reti¬nopathy of prematurity. Snellen visual acuity and structural
outcome at 5 1/2 years after randomization. Cryotherapy for
Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1996;
114: 417 -424.
12. Dobson V, Quinn GE, Abramov I et al. Color vision measured with
pseudoisochromatic plates at five-and-a-half years in eyes of
children from the CRYO-ROP study. Invest Ophthalmol VisSci 1996; 37:
2467-2474.
13. Gilbert WS, Quinn GE, Dobson V et al. Partial retinal detachment
at 3 months after threshold retinopathy of prematurity. Long-term
structural and functional outcome. Multicenter Trial of Cryotherapy
for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol
1996; 114: 1085 -1091.
14. Kivlin JD, Biglan AW, Gordon RA et al. Early retinal vessel
development and iris vessel dilatation as factors in retinopathy of
prematurity. Cryotherapy for Retinopathy of Prematurity (CRYO-ROP)
Cooperative Group. Arch Ophthalmol 1996; 114: 150 -154.
15. GE, Dobson V, Hardy RJ et al. Visual fields measured with
double-arc perimetry in eyes with threshold retinopathy of
prematurity from the cryotherapy for retinopathy of prematurity
trial. The CRYO-Retinopathy of Prematurity Cooperative Group.
Ophthalmology 1996; 103: 1432 -1437.
16. Dobson V, Quinn GE, Saunders RA et al. Grating visual acuity in
eyes with retinal residua of retinopathy of prematurity. The
Cryotherapy for Retinopathy of Prematurity Cooperative
Group.ArchOphthalmol 1995; 113:1172-1177.
17. Dobson V, Quinn GE, Tung B, Palmer EA, Reynolds JD. Comparison of
recognition and grating acuities in very-low-birthweight children
with and without retinal residua of retinopathy of prematurity.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Invest
Ophthalmol Vis Sci 1995; 36: 692 -702.
18. Quinn GE, Dobson V, Biglan A et al. Correlation of retinopathy of
prematurity in fellow eyes in the cryotherapy for retinopathy of
prematurity study. The Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Arch Ophthalmol 1995; 113: 469 -473.
19. The natural ocular outcome of premature birth and retinopathy.
Status at 1 year. Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Arch Ophthalmol 1994; 112: 903 -912.
20. Dobson V, Quinn GE, Summers CG et al. Effect of acute-phase
retinopathy of prematurity on grating acuity development in the very
low birth weight infant. The Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Invest Ophthalmol Vis Sci 1994;
35:4236 -4244.
21. Multicenter trial of cryotherapy for retinopathy of prematurity.
3 1/2-year outcome -structure and function. Cryotherapy for
Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1993;
111: 339-344.
22. Evans MS, Wallace PR, Palmer EA. Fundus Photography in small
infants. J Ophthal Photography 1993; 15:38-39.
23. Reynolds J, Dobson V, Quinn GE et al. Prediction of visual
function in eyes with mild to moderate posterior pole residua of
retinopathy of prematurity. Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Arch Ophthalmol 1993; 111: 1050 -1056.
24. Schaffer DB, Palmer EA, Plotsky DF et al. Prognostic factors in
the natural course of retinopathy of prematurity. The Cryotherapy for
Retinopathy of Prematurity Cooperative Group. Ophthalmology 1993;
100: 230 -237.
25. Gilbert WS, Dobson V, Quinn GE et al. The correlation of visual
function with posterior retinal structure in severe retinopathy of
prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative
Group. Arch Ophthalmol 1992; 110: 625-631.
26. Quinn GE, Dobson V, Repka M et al. Development of myopia in
infants with birth weights less than 1251 grams. The Cryotherapy for
Retinopathy of Prematurity Cooperative Group. Ophthalmology 1992; 99:
329 -340.
27. Summers G, Phelps DL, Tung B, Palmer EA. Ocular cosmesis in
retinopathy of prematurity. The Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Arch Ophthalmol 1992; 110: 1092 -1097.
28. Trueb L, Evans J, Hammel A, Bartholomew P, Dobson V. Assessing
visual acuity of visually impaired children using the Teller acuity
cards. Am Orthoptic J 1992; 2:149 -154.
29. Hardy RJ, Davis BR, Palmer EA, Tung B. Statistical considerations
in terminating randomization in the Multicenter Trial of Cryotherapy
for Retinopathy of Prematurity. Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Control Clin Trials 1991; 12: 293
-303.
30. Palmer EA, Flynn JT, Hardy RJ et al. Incidence and early course
of retinopathy of prematurity. The Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Ophthalmology 1991; 98: 1628-1640.
31. Palmer EA, Hardy RJ, Davis BR et al. Operational aspects of
terminating randomization in the Multicenter Trial of Cryotherapy for
Retinopathy of Prematurity. Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Control Clin Trials 1991; 12: 277-292.
32. Phelps DL, Brown DR, Tung B et al. 28-day survival rates of 6676
neonates with birth weights of 1250 grams or less. Pediatrics 1991;
87: 7-17.
33. Quinn GE, Dobson V, Barr CC et al. Visual acuity in infants after
vitrectomy for severe retinopathy of prematurity. Ophthalmology 1991;
98:5 -13.
34. (No authors listed). Multicenter trial of cryotherapy for
reti¬nopathy of prematurity. Three-month outcome. Cryotherapy for
Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1990;
108:195 -204.
35. Dobson V, Quinn GE, Biglan AW et al. Acuity card assessment of
visual function in the cryotherapy for retinopathy of pre-maturity
trial. Invest Ophthalmol Vis Sci 1990; 31: 1702-1708.
36. Watzke RC, Robertson JE Jr., Palmer EA et al. Photographic
grading in the retinopathy of prematurity cryotherapy trial. Arch
Ophthalmol 1990; 108: 950 -955 Multicenter trial of cryotherapy for
retinopathy of prematurity. Preliminary results.
37. Cryotherapy for Retinopathy of Prematurity Cooperative Group.
Arch Ophthalmol 1988; 106: 471-479.
38. Multicenter trial of cryotherapy for retinopathy of prematurity:
preliminary results. Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Pediatrics 1988; 81: 697-706.
39. Reynolds JD, Dobson V, Quinn GE et al. Evidence-based screening
criteria for retinopathy of prematurity: natural history data from
the CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol 2002; 120:
1470-1476.
40. Onofrey CB, Feuer WJ, Flynn JT. The outcome of retinopathy of
prematurity: screening for retinopathy of prematurity using an
outcome predictive program. Ophthalmology 2001; 108: 27-34;
discussion 34 -35.
41. Clemett R, Darlow B. Results of screening low-birth-weight
infants for retinopathy of prematurity. Curr Op in Ophthalmol 1999;
10: 155 -163.
42. (No authors listed). Multicenter trial of cryotherapy for
reti¬nopathy of prematurity. One-year outcome - structure and
function. Cryotherapy for Retinopathy of Prematurity Cooperative
Group. Arch Ophthalmol 1990; 108:1408-1416.
43. Palmer EA. Results of U.S. randomized clinical trial of
cryotherapy for ROP (CRYO-ROP). Doc Ophthalmol 1990; 74: 245-251.
44. Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK,
Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander
M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ,
Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler
BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT,
Smith LE, Tahija SG, Tasman W, Trese MT. Proceedings of the Third
International Symposium on Retinopathy of Prematurity: an update on
ROP from the lab to the nursery (November 2003, Anaheim, California).
Mol Vis. 2006 May 23;12:532-80.
45. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M,
Tung B; Early Treatment for Retinopathy of Prematurity Cooperative
Group. The incidence and course of retinopathy of prematurity:
findings from the early treatment for retinopathy of prematurity
study. Pediatrics. 2005 Jul;116(1):15-23.
46. Palmer EA, Hardy RJ, Dobson V, Phelps DL, Quinn GE, Summers CG,
Krom CP, Tung B; Cryotherapy for Retinopathy of Prematurity
Cooperative Group. 15-year outcomes following threshold retinopathy
of prematurity: final results from the multicenter trial of
cryotherapy for retinopathy of prematurity. Arch Ophthalmol. 2005
Mar;123(3):311-8.
47. Jandeck C, Kellner U, Heimann H, Foerster MH. [Comparison of the
anatomical and functional outcome after laser or cryotherapy for
retinopathy of prematurity (ROP)]. Ophthalmologe. 2005
Jan;102(1):33-8.
48. Repka MX, Tung B, Good WV, Shapiro M, Capone A Jr, Baker JD, Barr
CC, Phelps DL, van Heuven WA. Outcome of eyes developing retinal
detachment during the Early Treatment for Retinopathy of Prematurity
Study (ETROP). Arch Ophthalmol. 2006 Jan;124(1):24-30.
49. Jones JG, MacKinnon B, Good WV, Hardy RJ, Dobson V, Palmer EA,
Phelps DL, Quintos M, Tung B; Early Treatment for Retinopathy of
Prematurity Cooperative Group. The early treatment for ROP (ETROP)
randomized trial: study results and nursing care adaptations.
Insight. 2005 Apr-Jun;30(2):7-13. Review.
50. Final results of the Early Treatment for Retinopathy of
Prematurity (ETROP) randomized trial. Good WV; Early Treatment for
Retinopathy of Prematurity Cooperative Group. Trans Am Ophthalmol
Soc. 2004;102:233-48; discussion 248-50.
51. Phelps DL; ETROP Cooperative Group. The Early Treatment for
Retinopathy of Prematurity study: better outcomes, changing strategy.
Pediatrics. 2004 Aug;114(2):490-1.
Central Vein Occlusion Study (CVOS)
1. The Central Vein Occlusion Study Group. Natural history and
clinical management of central retinal vein occlusion. The Central
Vein Occlusion Study Group. Arch Ophthalmol 1997;115:486-491.
2. The Central Vein Occlusion Study Group. Evaluation of grid pattern
photocoagulation for macular edema in central vein occlusion. The
Central Vein Occlusion Study Group M report. Ophthalmology
1995;102:1425-1433.
3. The Central Vein Occlusion Study Group. A randomized clinical
trial of early pan-retinal photocoagulation for ischemic central vein
occlusion. The Central Vein Occlusion Study Group N report.
Ophthalmology 1995;102:1434 -1444.
4. Fekrat S, Finkelstein D. Current concepts in the management of
central retinal vein occlusion. Curr Op in Ophthalmol 1997;8:50-54.
5. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M,
Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup
SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of
dexamethasone intravitreal implant in patients with macular edema due
to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.
6. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle
AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizumab for
macular edema following central retinal vein occlusion: six-month
primary end point results of a phase III study. Ophthalmology. 2010
Jun;117(6):1124-1133.
7. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M,
Singerman LJ, mTolentino M, Chan CK, Gonzalez VH; SCORE Study
Research Group. A randomized trial comparing the efficacy and safety
of intravitreal triamcinolone with observation to treat vision
loss associated with macular edema secondary to central retinal vein
occlusion: the Standard Care vs Corticosteroid for Retinal Vein
Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009
Sep;127(9):1101-14.
8. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M,
Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research
Group. A randomized trial comparing the efficacy and safety of
intravitreal triamcinolone with standard care to treat vision loss
associated with macular Edema secondary to branch retinal vein
occlusion: the Standard Care vs Corticosteroid for Retinal Vein
Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009
Sep;127(9):1115-28.
9. Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ,
Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11
Incidences of neovascular events in eyes with retinal vein occlusion.
Ophthalmology. 2011 Mar 25. [Epub ahead of print].
Additional Background Reading
1. Clarkson JG. Central Vein Occlusion Study: photographic protocol
and early natural history. Trans Am Ophthalmol Soc 1994;92:203-213.
Discussion 213-215.
2. (No authors listed). Baseline and early natural history report.
The Central Vein Occlusion Study. Arch Ophthalmol 1993;111:1087-1095.
3. Soubrane G. Macular edema in retinal vein occlusion: up-date from
the central retinal vein occlusion study. Doc Ophthalmol 1999;97:279
-281.
Diabetes Control and Complications Trial (DCCT)
1. (No authors listed). Lifetime benefits and costs of intensive
therapy as practiced in the diabetes control and complications trial.
The Diabetes Control and Complications Trial Research Group. Jama
1996; 276: 1409 -1415.
2. (No authors listed). The effect of intensive treatment of diabetes
on the development and progression of long-term complications in
insulin-dependent diabetes mellitus. The Diabetes Control and
Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
3. (No authors listed). Progression of retinopathy with intensive
versus conventional treatment in the Diabetes Control and
Complications Trial. Diabetes Control and Complications Trial
Research Group. Ophthalmology 1995; 102: 647 -661.
4. (No authors listed). Early worsening of diabetic retinopathy in
the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;
116: 874-886 [Erratum appears in Arch Ophthalmol 1998; 1116: 1469].
5. (No authors listed). The effect of intensive diabetes treatment on
the progression of diabetic retinopathy in insulin-dependent diabetes
mellitus. The Diabetes Control and ComplicationsTrial. Arch
Ophthalmol 1995; 113:36-51.
6. Barr CC. Retinopathy and nephropathy in patients with type 1
diabetes four years after a trial of intensive therapy. The Diabetes
Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications Research Group. N Engl J Med 2000;
342: 381 -389.
7. Eastman RC, Javitt JC, Herman WH et al. Model of complications of
NIDDM. II. Analysis of the health benefits and cost-effectiveness of
treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;
20: 735-744.
8. Klein R, Klein BE. Relation of glycemic control to diabetic
complications and health outcomes. Diabetes Care 1998; 21, Suppl 3:
C39 -43.
Additional Background Reading
1. Peterson KA, Smith CK. The DCCT findings and standards of care for
diabetes. Am Fam Physician 1995; 52: 1092 -1098.
2. Leiter LA. Use of bioelectrical impedance analysis measurements in
patients with diabetes. The Diabetes Control and Complications Trial
Research Group. Am J Clin Nutr 1996; 64: 515S -518S.
3. (No authors listed). Epidemiology of severe hypoglycemia in the
diabetes control and complications trial. The DCCT Research Group. Am
J Med 1991; 90:450 -459.
4. (No authors listed). Effect of intensive therapy on residual
beta-cell function in patients with type 1 diabetes in the diabetes
control and complications trial. A randomized, controlled trial. The
Diabetes Control and Complications Trial Research Group. Ann Intern
Med 1998; 128: 517 -523.
5. (No authors listed). The effect of intensive diabetes therapy on
the development and progression of neuropathy. The Diabetes Control
and Complications Trial Research Group. Ann Intern Med 1995; 122:561
-568.
6. (No authors listed). Color photography vs fluorescein angiography
in the detection of diabetic retinopathy in the diabetes control and
complications trial. The Diabetes Control and Complications Trial
Research Group. Arch Ophthalmol 1987; 105: 1344-1351.
7. Worrall G. Results of the DCCT trial. Implications for managing
our patients with diabetes. Can Fam Physician 1994; 40: 1955-1960,
1963 -1965.
8. Hoogwerf BJ, Brouhard BH. Glycemic control and complications of
diabetes mellitus: practical implications of the Diabetes Control and
Complications Trial (DCCT). Cleve Clin J Med 1994; 61:34-37; quiz 80
-82.
9. (No authors listed). Feasibility of centralized measurements of
glycated hemoglobin in the Diabetes Control and Complications Trial:
a multicenter study. The DCCT Research Group. Clin Chem 1987; 33:
2267-2271.
10. (No authors listed). Implementation of a multicomponent process
to obtain informed consent in the Diabetes Control and Complications
Trial. The DCCT Research Group. Control Clin Trials 1989; 10: 83-96.
11. (No authors listed). Clustering of long-term complications in
families with diabetes in the diabetes control and complications
trial. The Diabetes Control and Complications Trial Research Group.
Diabetes 1997; 46: 1829-1839.
12. (No authors listed). Factors in development of diabetic
neuropathy. Baseline analysis of neuropathy in feasibility phase of
Diabetes Control and Complications Trial (DCCT). The DCCT Research
Group. Diabetes 1988; 37: 476-481.
13. (No authors listed). Hypoglycemia in the Diabetes Control and
Complications Trial. The Diabetes Control and Complications Trial
Research Group. Diabetes 1997; 46: 271 -286.
14. Monnier VM, Bautista O, Kenny D et al. Skin collagen glyca¬tion,
glycoxidation, and crosslinking are lower in subjects with long-term
intensive versus conventional therapy of type 1 diabetes: relevance
of glycated collagen products versus HbA1c as markers of diabetic
complications. DCCT Skin Collagen Ancillary Study Group. Diabetes
Control and Complications Trial. Diabetes 1999; 48: 870-880.
15. (No authors listed). The Diabetes Control and Complications Trial
(DCCT). Design and methodologic considerations for the feasibility
phase. The DCCT Research Group. Diabetes 1986; 35: 530 -545.
16. Gautier JF, Beressi JP, Leblanc H, Vexiau P, Passa P. Are the
implications of the Diabetes Control and Complications Trial (DCCT)
feasible in daily clinical practice? Diabetes Metab 1996; 22: 415
-419.
17. McCulloch DK, Glasgow RE, Hampson SE, Wagner E. A systematic
approach to diabetes management in the post-DCCT era. Diabetes Care
1994; 17: 765-769.
18. Moses RG, Rodgers DV, Griffiths RD. Clinic variations hold
important clues to the understanding and implementation of the DCCT
results. Diabetes Care 1996; 19: 178-180.
19. Dagogo-Jack S. DCCT results and diabetes care in developing
countries. Diabetes Care 1995; 18: 416 -417.
20. (No authors listed). Diabetes Control and Complications Trial
(DCCT): results of feasibility study. The DCCT Research Group.
Diabetes Care 1987; 10: 1-19.
21. (No authors listed). Diabetes Control and Complications Trial
(DCCT). Update. DCCT Research Group. Diabetes Care 1990; 13: 427-433.
22. (No authors listed). Effect of pregnancy on microvascular
complications in the diabetes control and complications trial. The
Diabetes Control and Complications Trial Research Group. Diabetes
Care 2000; 23: 1084 -1091.
23. Orchard TJ. From diagnosis and classification to complications
and therapy. DCCT. Part II Diabetes Control and Complications Trial.
Diabetes Care 1994; 17: 326-338.
24. Thompson CJ, Cummings JF, Chalmers J, Gould C, Newton RW. How
have patients reacted to the implications of the DCCT? Diabetes Care
1996; 19: 876 -879.
25. Rubin RR, Peyrot M. Implications of the DCCT. Looking beyond
tight control. Diabetes Care 1994; 17: 235 -236.
26. (No authors listed). Lipid and lipoprotein levels in patients
with IDDM diabetes control and complication. Trial experience. The
DCCT Research Group. Diabetes Care 1992; 15: 886 -894.
27. (No authors listed). Reliability and validity of a diabetes
quality-of-life measure for the diabetes control and complications
trial (DCCT). The DCCT Research Group. Diabetes Care 1988; 11: 725
-732.
28. Harris MI, Eastman RC, Siebert C. The DCCT and medical care for
diabetes in the U.S. Diabetes Care 1994; 17:761-764.
29. (No authors listed). Weight gain associated with intensive
therapy in the diabetes control and complications trial. The DCCT
Research Group. Diabetes Care 1988; 11: 567 -573.
30. (No authors listed). AADE position statement: Diabetes Control
and Complications Trial (DCCT). Diabetes Educ 1994; 20: 106, 108.
31. Ahern JA, Kruger DF, Gatcomb PM, Petit WA Jr., Tamborlane WV. The
diabetes control and complications trial (DCCT): the trial
coordinator perspective. Report by the DCCT Research Group. Diabetes
Educ 1989; 15: 236-241.
32. Ahern J, Grove N, Strand T et al. The impact of the Trial
Coordinator in the Diabetes Control and Complications Trial (DCCT).
The DCCT Research Group. Diabetes Educ 1993; 19: 509 -512.
33. Ahern JA, Ramchandani N, Cooper J et al. Using a primary nurse
manager to implement DCCT recommendations in a large pediatric
program. Diabetes Educ 2000; 26: 990-994.
34. Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better
glycaemic control and risk reduction of diabetic complications in
Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract
1998; 42:77-83.
35. (No authors listed). Implementing the lessons of DCCT. Report of
a national workshop under the auspices of the British Diabetic
Association. Diabet Med 1994; 11: 220 -228.
36. Gibb I, Parnham AJ, Lord C et al. Standardization of glycated
haemoglobin assays throughout the Northern region of England: a pilot
study. Diabet Med 1997; 14: 584-588.
37. (No authors listed). The effect of intensive diabetes therapy on
measures of autonomic nervous system function in the Diabetes Control
and Complications Trial (DCCT). Diabetologia 1998; 41:416 -423.
38. Zinman B. Translating the Diabetes Control and Complications
Trial (DCCT) into clinical practice: overcoming the barriers.
Diabetologia 1997; 40 Suppl 2: S88 -90.
39. Szucs TD, Smala AM, Fischer T. [Costs of intensive insulin
therapy in type 1 diabetes mellitus]. Experiences from the DCCT
study. Fortschr Med 1998; 116:34 -38.
40. German Leiter LA, Lukaski HC, Kenny DJ et al. The use of
bioelectrical impedance analysis (BIA) to estimate body composition
in the Diabetes Control and Complications Trial (DCCT). Int J Obes
Relat Metab Disord 1994; 18: 829 -835.
41. Purnell J, Hokanson JE, Marcovina SM et al. Effect of excessive
weight gain with intensive therapy of type 1 diabetes on lipid levels
and blood pressure: results from the DCCT. Diabetes Control and
Complications Trial. Jama 1998; 280: 140-146 [Erratum appears in JAMA
1998 1994; 1280:1841].
42. (No authors listed). A screening algorithm to identify clinically
significant changes in neuropsychological functions in the Diabetes
Control and Complications Trial. DCCT Research Group. J Clin Exp
Neuropsychol 1994;16: 303-316.
43. (No authors listed). Effects of age, duration and treatment of
insulin-dependent diabetes mellitus on residual beta-cell function:
observations during eligibility testing for the Diabetes Control and
Complications Trial (DCCT). The DCCT Research Group. J Clin
Endocrinol Metab 1987; 65: 30 -36.
44. White NH, Cleary PA, Dahms W et al. Beneficial effects of
intensive therapy of diabetes during adolescence: outcomes after the
conclusion of the Diabetes Control and Complications Trial (DCCT). J
Pediatr 2001; 139: 804 -812.
45. (No authors listed). Effect of intensive diabetes treatment on
the development and progression of long-term complications in
adolescents with insulin-dependent diabetes mellitus: Diabetes
Control and Complications Trial. Diabetes Control and Complications
Trial Research Group. J Pediatr 1994; 125: 177 -188.
46. Moses R, Rodgers D, Griffiths R. Diabetic control and
hypoglycaemia in the Illawarra area of NSW, Australia: a comparison
with the DCCT. J Qual Clin Pract 1995; 15: 89-97.
47. Delahanty L, Simkins SW, Camelon K. Expanded role of the
dietitian in the Diabetes Control and Complications Trial:
implications for clinical practice. The DCCT Research Group. J Am
Diet Assoc 1993; 93:758-764,767.
48. Anderson EJ, Richardson M, Castle G et al. Nutrition
interventions for intensive therapy in the Diabetes Control and
Complications Trial. The DCCT Research Group. J Am Diet Assoc 1993;
93: 768 -772.
49. Schmidt LE, Cox MS, Buzzard IM, Cleary PA. Reproducibility of a
comprehensive diet history in the Diabetes Control and Complications
Trial. The DCCT Research Group. J Am Diet Assoc 1994; 94: 1392 -1397.
50. Levey AS, Greene T, Schluchter MD et al. Glomerular filtration
rate measurements in clinical trials. Modification of Diet in Renal
Disease Study Group and the Diabetes Control and Complications Trial
Research Group. J Am Soc Nephrol 1993; 4: 1159 -1171.
51. Molitch ME, Steffes MW, Cleary PA, Nathan DM. Baseline analysis
of renal function in the Diabetes Control and Complications Trial.
The Diabetes Control and Complications Trial Research Group
[corrected]. Kidney Int 1993; 43: 668 -674.
52. (No authors listed). Effect of intensive therapy on the
devel¬opment and progression of diabetic nephropathy in the Diabetes
Control and Complications Trial. The Diabetes Control and
Complications (DCCT) Research Group. Kidney Int 1995; 47: 1703-1720.
53. Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR.
Serum C-peptide concentrations poorly phenotype type 2 diabetic
end-stage renal disease patients. Kidney Int 2000; 58: 1742-1750.
54. Chrisholm DJ. The Diabetes Control and Complications Trial
(DCCT). A milestone in diabetes management. Med J Aust 1993; 159:
721-723.
55. Nosadini R, Abaterusso C, Dalla Vestra M et al. Efficacy of
antihypertensive therapy in decreasing renal and cardiovascular
complications in diabetes mellitus. Nephrol Dial Transplant 1998; 13
Suppl 8: 44-48.
56. Rapaport R, Sills IN. Implications of the DCCT for children and
adolescents with IDDM. N J Med 1994; 91:227 -228.
57. (No authors listed). Effect of intensive diabetes management on
macrovascular events and risk factors in the Diabetes Control and
Complications Trial. Am J Cardiol 1995; 75: 894 -903.
58. Schwartz R, Teramo KA. Pregnancy outcome, Diabetes Control and
Complications Trial, and intensive glycemic control. Am J Obstet
Gynecol 1998; 178: 416-417.
59. (No authors listed). Pregnancy outcomes in the Diabetes Control
and Complications Trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
60. (No authors listed). Effect of intensive therapy on the
micro-vascular complications of type 1 diabetes mellitus. Jama 2002;
287: 2563 -2569.
61. (No authors listed). Effects of intensive diabetes therapy on
neuropsychological function in adults in the Diabetes Control and
Complications Trial. Ann Intern Med 1996; 124: 379 -388.
62. Brink SJ. How to apply the experience from the diabetes con¬trol
and complications trial to children and adolescents? Ann Med1997;
29:425-438.
63. (No authors listed). Effect of intensive diabetes treatment on
nerve conduction in the Diabetes Control and Complications Trial. Ann
Neurol 1995; 38:869-880.
64. Carlisle BA. The implications of diabetes control and
complications trial for the pharmacy profession. Ann Pharmac other
1996; 30: 294 -295.
65. Klein R, Moss S. A comparison of the study populations in the
Diabetes Control and Complications Trial and the Wisconsin
Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 1995;
155: 745-754.
66. Duron F. Intensive insulin therapy in insulin-dependent diabetes
mellitus, the results of the diabetes control and complications
trial. Biomed Pharma cother1995; 49: 278 -282.
67. Newman RJ. A method to implement the recommendations of the
diabetes control and complications trial in a busy pediatric
outpatient practice. Pediatr Ann 1999; 28:594-598.
68. Fenton CL, Clemons PM, Francis GL. How do the results of the
diabetes control and complications trial relate to the practice of
pediatrics: who should have intensive management? Pediatr Ann 1999;
28: 600-604.
69. Malone JI. Lessons for pediatricians from the diabetes control
and complications trial. Pediatr Ann 1994; 23:295-299.
70. Tamborlane WV, Ahern J. Implications and results of the Diabetes
Control and Complications Trial. Pediatr Clin North Am 1997; 44:
285-300.
71. Vinik AI, Richardson DW. Implications of the diabetes control and
complications trial for persons with non-insulin-dependent diabetes
mellitus. South Med J 1997; 90:268 -282.
72. Saudek CD. Non-ophthalmologic findings of the Diabetes Control
and Complications Trial. Surv Ophthalmol 1995; 40: 157-162.
73. Nuttall F. Comparison of percent total GHb with percent HbA1c in
people with and without known diabetes. Diabetes Care 1998; 21:
1475-1480.
74. Ruggiero L, Glasgow R, Dryfoos JM et al. Diabetes
self-management. Self-reported recommendations and patterns in a
large population. Diabetes Care 1997; 20:568-576.
75. Levin SR, Coburn JW, Abraira C et al. Effect of intensive
glyce¬mic control on microalbuminuria in type 2 diabetes. Veterans
Affairs Cooperative Study on Glycemic Control and Complications in
Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000;
23: 1478-1485.
76. Rosilio M, Cotton JB, Wieliczko MC et al. Factors associated with
glycemic control. A cross-sectional nationwide study in 2,579 French
children with type 1 diabetes. The French Pediatric Diabetes Group.
Diabetes Care 1998; 21:1146-1153.
77. (No authors listed). Factors influencing glycemic control in
young people with type 1 diabetes in Scotland: a population-based
study (DIABAUD2). Diabetes Care 2001; 24:239-244.
78. Yokoyama H, Okudaira M, Otani T et al. High incidence of diabetic
nephropathy in early-onset Japanese NIDDM patients. Risk analysis.
Diabetes Care 1998; 21:1080-1085.
79. Dunn FL, Nathan DM, Scavini M, Selam JL, Wingrove TG. Long-term
therapy of IDDM with an implantable insulin pump. The Implantable
Insulin Pump Trial Study Group. Diabetes Care 1997; 20:59-63.
80. Miller CD, Phillips LS, Tate MK et al. Meeting American Diabetes
Association guidelines in endocrinologist practice. Diabetes Care
2000; 23:444-448.
81. Eastman RC, Javitt JC, Herman WH et al. Model of complications of
NIDDM. I. Model construction and assumptions. Diabetes Care 1997;
20:725-734
82. Keen H. The Diabetes Control and Complications Trial (DCCT).
Health Trends 1994; 26: 41-43.
83. Tercyak KP Jr., Johnson SB, Kirkpatrick KA, Silverstein JH.
Offering a randomized trial of intensive therapy for IDDM to
adolescents. Reasons for refusal, patient characteristics, and
recruiter effects. Diabetes Care 1998; 21:213-215.
84. Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality
of life and associated characteristics in a large national sample of
adults with diabetes. Diabetes Care 1997; 20:562-567.
Diabetic Retinopathy Study (DRS)
1. (No authors listed). Indications for photocoagulation treatment of
diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The
Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987;
27:239-253.
2. Kaufman SC, Ferris FL 3rd, Seigel DG, Davis MD, DeMets DL. Factors
associated with visual outcome after photocoagulation for diabetic
retinopathy. Diabetic Retinopathy Study Report 13. Invest Ophthalmol
Vis Sci 1989; 30:23-28.
3. Ferris FL 3rd, Podgor MJ, Davis MD. Macular edema in Diabetic
Retinopathy Study patients. Diabetic Retinopathy Study Report Number
12. Ophthalmology 1987; 94:754-760.
4. Rand LI, Prud'homme GJ, Ederer F, Canner PL. Factors influencing
the development of visual loss in advanced diabetic retinopathy.
Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis
Sci 1985; 26:983-991.
Additional Background Reading
1. Kaufman SC, Ferris FL 3rd, Swartz M. Intraocular pressure
following panretinal photocoagulation for diabetic retinopathy.
Diabetic Retinopathy Report No. 11. Arch Ophthalmol 1987;
105:807-809.
2. Ederer F, Podgor MJ. Assessing possible late treatment effects in
stopping a clinical trial early: a case study. Diabetic Retinopathy
Study report No. 9. Control Clin Trials 1984; 5:373-381.
3. (No authors listed). Diabetic retinopathy study. Report Number 6.
Design, methods, and baseline results. Report Number 7. A
modification of the Airlie House classification of diabetic
retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol
Vis Sci 1981; 21:1-226.
4. Photocoagulation treatment of proliferative diabetic retinopathy:
relationship of adverse treatment effects to retinopathy severity.
Diabetic retinopathy study report no. 5. Dev Ophthalmol 1981;
2:248-261.
5. (No authors listed). Photocoagulation treatment of proliferative
diabetic retinopathy. Clinical application of Diabetic Retinopathy
Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy
Study Research Group. Ophthalmology 1981; 88:583-600.
6. (No authors listed). Four risk factors for severe visual loss in
diabetic retinopathy. The third report from the Diabetic Retinopathy
Study. The Diabetic Retinopathy Study Research Group. Arch Ophthalmol
1979; 97:654-655.
7. Preliminary report on effects of photocoagulation therapy. The
Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976; 81:
383-396.
Early Treatment Diabetic Retinopathy Study (ETDRS)
1. Fong DS, Ferris FL 3rd, Davis MD, Chew EY. Causes of severe visual
loss in the early treatment diabetic retinopathy study: ETDRS report
no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am
J Ophthalmol 1999; 127:137 -141.
2. Chew EY, Klein ML, Murphy RP, Remaley NA, Ferris FL 3rd. Effects
of aspirin on vitreous/preretinal hemorrhage in patients with
diabetes mellitus. Early Treatment Diabetic Retinopathy Study report
no. 20. Arch Ophthalmol 1995; 113: 52-55.
3. (No authors listed). Focal photocoagulation treatment of diabetic
macular edema. Relationship of treatment effect to fluorescein
angiographic and other retinal characteristics at baseline: ETDRS
report no. 19. Early Treatment Diabetic Retinopathy Study Research
Group. Arch Ophthalmol 1995; 113: 1144 -1155.
4. (No authors listed). Early photocoagulation for diabetic
retinopathy. ETDRS report number 9. Early Treatment Diabetic
Retinopathy Study Research Group. Ophthalmology 1991; 98:766-785.
5. (No authors listed). Grading diabetic retinopathy from
stereoscopic color fundus photographs -an extension of the modified
Airlie House classification. ETDRS report number 10. Early Treatment
Diabetic Retinopathy Study Research Group. Ophthalmology 1991;
98:786-806.
6. (No authors listed). Classification of diabetic retinopathy from
fluorescein angiograms. ETDRS report number 11. Early Treatment
Diabetic Retinopathy Study Research Group. Ophthalmology 1991;
98:807-822.
7. (No authors listed). Fundus photographic risk factors for
progression of diabetic retinopathy. ETDRS report number 12. Early
Treatment Diabetic Retinopathy Study Research Group. Ophthalmology
1991 May; 98 (5Suppl):823-33.
8. (No authors listed). Treatment techniques and clinical guidelines
for photocoagulation of diabetic macular edema. Early Treatment
Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic
Retinopathy Study Research Group. Ophthalmology 1987; 94:761-774.
9. (No authors listed). Techniques for scatter and local
photocoagulation treatment of diabetic retinopathy: Early Treatment
Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic
Retinopathy Study Research Group. Int Ophthalmol Clin 1987;
27:254-264.
10. Fong DS, Segal PP, Myers F et al. Subretinal fibrosis in diabetic
macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy
Study Research Group. Arch Ophthalmol 1997; 115:873-877.
Additional Background Reading
1. Fong DS, Barton FB, Bresnick GH. Impaired color vision associated
with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study
Report No. 15. Am J Ophthalmol 1999; 128: 612-617.
2. Chew EY, Klein ML, Ferris FL 3rd et al. Association of elevated
serum lipid levels with retinal hard exudate in diabetic retinopathy.
Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch
Ophthalmol 1996; 114 :1079-1084.
3. Ferris F. Early photocoagulation in patients with either type I or
type II diabetes. Trans Am Ophthalmol Soc 1996; 94:505-537.
4. Ferris FL 3rd, Chew EY, Hoogwerf BJ. Serum lipids and diabetic
retinopathy. Early Treatment Diabetic Retinopathy Study Research
Group. Diabetes Care 1996; 19:1291-1293.
5. Braun CI, Benson WE, Remaley NA, Chew EY, Ferris FL 3rd.
Accommodative amplitudes in the Early Treatment Diabetic Retinopathy
Study. Retina 1995; 15: 275-281.
6. Prior MJ, Prout T, Miller D, Ewart R, Kumar D. C-peptide and the
classification of diabetes mellitus patients in the Early Treatment
Diabetic Retinopathy Study. Report number 6. The ETDRS Research
Group. Ann Epidemiol 1993; 3:9-17.
7. (No authors listed). Aspirin effects on mortality and morbidity in
patients with diabetes mellitus. Early Treatment Dia¬betic
Retinopathy Study report 14. ETDRS Investigators. Jama
1992;268:1292-1300.
8. Chew EY, Williams GA, Burton TC et al. Aspirin effects on the
development of cataracts in patients with diabetes mellitus. Early
treatment diabetic retinopathy study report 16. Arch Ophthalmol
1992;110:339-342.
9. Flynn HW Jr., Chew EY, Simons BD et al. Pars plana vitrectomy in
the Early Treatment Diabetic Retinopathy Study. ETDRS report number
17. The Early Treatment Diabetic Retinopathy Study Research Group.
Ophthalmology 1992;99:1351-1357.
10. (No authors listed). Early Treatment Diabetic Retinopathy Study
design and baseline patient characteristics. ETDRS report number 7.
Ophthalmology 1991;98:741-756.
11. (No authors listed). Effects of aspirin treatment on diabetic
retinopathy. ETDRS report number 8. Early Treatment Diabetic
Retinopathy Study Research Group. Ophthalmology 1991;98:757-765.
12. (No authors listed). Fluorescein angiographic risk factors for
progression of diabetic retinopathy. ETDRS report number 13. Early
Treatment Diabetic Retinopathy Study Research Group. Ophthalmology
1991;98:834-840.
13. Kinyoun J, Barton F, Fisher M et al. Detection of diabetic
macular edema. Ophthalmoscopy versus photography -Early Treatment
Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group.
Ophthalmology 1989; 96:746 -750; discussion 750-751.
14. (No authors listed). Photocoagulation for diabetic macular edema:
Early Treatment Diabetic Retinopathy Study Report no. 4. The Early
Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol
Clin 1987;27:265-272.
15. (No authors listed). Photocoagulation for diabetic macular edema.
Early Treatment Diabetic Retinopathy Study report number 1. Early
Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol
1985;103:1796-1806.
16. Ferris FL 3rd. Photocoagulation for diabetic retinopathy. Early
Treatment Diabetic Retinopathy Study Research Group. Jama
1991;266:1263-1265.
17. (No authors listed). Case reports to accompany Early Treatment
Diabetic Retinopathy Study Reports 3 and 4. The Early Treatment
Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin
1987;27:273-333.
18. (No authors listed). Photocoagulation therapy for diabetic eye
disease. Early Treatment Diabetic Retinopathy Study Research Group.
Jama 1985;254:3086.
XII. Uveitis and Ocular Inflammation
Epidemiology
Epidemiology
1. Jabs DA. Epidemiology of uveitis. Ophthalmic Epidemiol. 2008
Sep-Oct;15(5):283-4.
Evaluation and Grading
1. Bloch-Michel E, Nussenblat RB. International Uveitis Study Group
Recommendations for the evaluation of intraocular inflammatory
disease. Am J Ophthalmol 1987;103:234-235.
2. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis
Nomenclature (SUN) Working Group. Standardization of uveitis
nomenclature for reporting clinical data. Results of the First
International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16
3. Tugal-Tutkun I, Herbort CP, Khairallah M, Mantovani A.
Interobserver agreement in scoring of dual fluorescein and ICG
inflammatory angiographic signs for the grading of posterior segment
inflammation. Ocul Immunol Inflamm. 2010 Oct;18(5):385-9.
4. Mahendradas P, Shetty R, Narayana KM, Shetty BK. In vivo confocal
microscopy of keratic precipitates in infectious versus noninfectious
uveitis. Ophthalmology 2010;117:373-380.
5. Kempen JH,
Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in
grading activity and site of inflammation in eyes of patients with
uveitis. Am J Ophthalmol. 2008 Dec;146(6):813-8.e1.
Approach to Uveitis
1. Herbort CP. Appraisal, work-up and diagnosis of anterior uveitis:
a practical approach. Middle East Afr J Ophthalmol. 2009
Oct;16(4):159-67.
2. Agrawal RV, Murthy S, Sangwan V, Biswas J. Current approach in
diagnosis and management of anterior uveitis. Indian J Ophthalmol.
2010 Jan-Feb;58(1):11-9.
3. Sudharshan S, Ganesh SK, Biswas J. Current approach in the
diagnosis and management of posterior uveitis. Indian J Ophthalmol.
2010 Jan-Feb;58(1):29-43.
4. Bansal R, Gupta V, Gupta A. Current approach in the diagnosis and
management of panuveitis. Indian J Ophthalmol. 2010
Jan-Feb;58(1):45-54.
5. Babu BM, Rathinam SR. Intermediate uveitis. Indian J Ophthalmol.
2010 Jan-Feb;58(1):21-7.
6. Mahendradas P, Shetty R, Narayana KM, Shetty BK. In vivo confocal
microscopy of keratic precipitates in infectious versus noninfectious
uveitis. Ophthalmology 2010;117:373-380.
Scleritis/Episcleritis
1. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis:
clinical features and treatment results. Am J Ophthalmol 2000; 130:
469 -476.
Anterior Uveitis
1. Tay-Kearney ML, Schwam BL, Lowder C et al. Clinical features and
associated systemic diseases of HLA-B27 uveitis. Am J Ophthalmol
1996; 121: 47 -56.
Infectious Uveitis
1. Khairallah M, Chee SP, Rathinam SR, Attia S, Nadella V. Novel
infectious agents causing uveitis. Int Ophthalmol. 2010
Oct;30(5):465-83.
2. Ur Rehman S, Anand S, Reddy A, Backhouse OC, Mohamed M, Mahomed I,
Atkins AD, James T. Poststreptococcal syndrome uveitis: a descriptive
case series and literature review. Ophthalmology. 2006
Apr;113(4):701-6.
3. Van Gelder RN. Ocular pathogens for the twenty-first century. Am J
Ophthalmol. 2010 Nov;150(5):595-7.
4. Rathinam SR, Ashok KA. Ocular manifestations of systemic disease:
ocular parasitosis. Curr Opin Ophthalmol. 2010 Nov;21(6):478-84.
5. Mahendradas P, Ranganna SK, Shetty R et al. Ocular manifestations
associated with Chikungunya. Ophthalmology 2008;115:287-291.
6. Dengue-associated maculopathy. Bacsal KE, Chee SP, Cheng CL,
Flores JV. Arch Ophthalmol. 2007 Apr; 125(4):501-10
Herpetic Disease
1. Tugal-Tutkun I, Otűk-Yasar B, Altinkurt E. Clinical features and
prognosis of herpetic anterior uveitis: a retrospective study of 111
cases. Int Ophthalmol. 2010 Oct;30(5):559-65.
2. Green LK, Pavan-Langston D. Herpes simplex ocular inflammatory
disease. Int Ophthalmol Clin. 2006 Spring;46(2):27-37.
3. Herpetic Eye disease Study Group. Acyclovir for the prevention of
recurrent herpes simplex virus eye disease. N Engl J Med 1998;
339:300-306.
4. Uchoa UB, Rezende RA, Carrasco MA et al. Long term acyclovir use
to prevent recurrent ocular herpes simplex virus infection. Arch
Ophthalmol 2003; 121:1702-1704.
5. Chee SP, Bacsal K, Jap A et al. Clinical features of
cytomegalovirus anterior uveitis in immunocompetent patients. Am J
Ophthalmol 2008;145:834-840.
6. Chee SP, Jap A. Presumed fuchs heterochromic iridocyclitis and
Posner-Schlossman syndrome: comparison of cytomegalovirus-positive
and negative eyes. Am J Ophthalmol 2008; 146:883-889.
7. Chee SP, Jap A. Cytomegalovirus anterior uveitis: outcome of
treatment. Br J Ophthalmol 2010; 94:,1648-1652.
Fuchs Uveitis Syndrome
1. Mohamed Q, Zamir E. Update on Fuchs' uveitis syndrome. Curr Opin
Ophthalmol. 2005 Dec;16(6):356-63.
2. Al-Mansour YS, Al-Rajhi AA, Al-Dhibi H, Abu El-Asrar AM. Clinical
features and prognostic factors in Fuchs' uveitis. Int Ophthalmol.
2010 Oct;30(5):501-9.
3. Quentin CD, Reiber H. Fuchs heterochromic cyclitis: rubella virus
antibodies and genome in aqueous humor. Am J Ophthalmol
2004;138:46-54.
4. Bouchenaki N, Herbort CP. Fluorescein angiographic findings and
clinical features in Fuchs' uveitis. Int Ophthalmol 2010;30:511-519.
Cytomegalovirus Retinitis (CMV)
1. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery
uveitis in patients with AIDS and cytomegalovirus retinitis after
highly active antiretroviral therapy. Am J Ophthalmol 2000; 129: 634
-639.
2. Robinson MR, Reed G, Csaky KG, Polis MA, Whitcup SM.
Immune-recovery uveitis in patients with cytomegalovirus retinitis
taking highly active antiretroviral therapy. Am J Ophthalmol 2000;
130: 49 -56.
Toxoplasmosis
1. Dodds EM. Toxoplasmosis. Curr Opin Ophthalmol. 2006
Dec;17(6):557-61.
White Dot Syndromes
1. Quillen DA, Davis JB, Gottlieb JL, Blodi BA,
Callanan DG, Chang TS, Equi RA. The white dot syndromes. Am J
Ophthalmol. 2004 Mar;137(3):538-50.
Sarcoidosis
1. Herbort CP, Rao NA, Mochizuki M; Member,s of Scientific Committee
of First International Workshop on Ocular Sarcoidosis. International
criteria for the diagnosis of ocular sarcoidosis: results of the
first International Workshop On Ocular Sarcoidosis (IWOS). Ocul
Immunol Inflamm. 2009 May-Jun;17(3):160-9.
Tuberculosis
1. Gupta V, Gupta A, Rao NA. Intraocular tuberculosis--an update.
Surv Ophthalmol. 2007 Nov-Dec;52(6):561-87.
2. Diagnosis of tuberculous uveitis: clinical application of an
interferon-gamma release assay. Ang M, Htoon HM, Chee SP.
Ophthalmology. 2009 Jul;116(7):1391-6.
Behçet Disease
1. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H.
Ocular features of Behçet's disease: an international collaborative
study. Br J Ophthalmol. 2007 Dec;91(12):1579-82.
2. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A,
Houman MH, Kőtter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A,
Stanford MR, Stübiger N, Yurdakul S, Yazici H; EULAR Expert
Committe. EULAR recommendations for the management of Behçet
disease. Ann Rheum Dis. 2008 Dec;67(12):1656-62.
3. Evereklioglu C. Current concepts in the etiology and treatment of
Behçet disease. Surv Ophthalmol. 2005 Jul-Aug;50(4):297-350.
Vogt Koyanagi Harada Disease and Sympathetic Ophthalmia
1. Nussenblatt RB. Clinical studies of Vogt-Koyanagi-Harada's disease
at the National Eye Institute, NIH, USA. Jpn J Ophthalmol 1988; 32:
330-333.
2. Rao NA, Sukavatcharin S, Tsai JH. Vogt-Koyanagi-Harada disease
diagnostic criteria. Int Ophthalmol. 2007 Apr-Jun;27(2-3):195-9.
3. Lertsumitkul S, Whitcup SM, Nussenblatt RB, Chan CC. Sub-retinal
fibrosis and choroidal neovascularization in Vogt Koyanagi-Harada
syndrome. Graefes Arch Clin Exp Ophthalmol 1999; 237: 1039 -1045.
4. Da Silva FT, Damico FM, Marin ML, Goldberg AC, Hirata CE, Takiuti
PH, Olivalves E, Yamamoto JH. Revised diagnostic criteria for
vogt-koyanagi-harada disease: considerations on the different disease
categories. Am J Ophthalmol. 2009 Feb;147(2):339-345.e5.
5. Chan CC, Roberge RG, Whitcup SM, Nussenblatt RB. 32 cases of
sympathetic ophthalmia. A retrospective study at the National Eye
Institute, Bethesda, Md., from 1982 to 1992. Arch Ophthalmol 1995;
113: 597-600. [Erratum appears in Arch Ophthalmol 1995; 113: 1507].
6. Galor A, Davis JL, Flynn HW Jr, Feuer WJ, Dubovy SR, Setlur V,
Kesen MR, Goldstein DA, Tessler HH, Ganelis IB, Jabs DA, Thorne JE.
Sympathetic ophthalmia: incidence of ocular complications and vision
loss in the sympathizing eye. Am J Ophthalmol. 2009
Nov;148(5):704-710.e2.
Masquerade Sydromes
1. Rothova A, Ooijman F, Kerkhoff F, Van Der Lelij A, Lokhorst HM.
Uveitis masquerade syndromes. Ophthalmology. 2001 Feb;108(2):386-99.
Cystoid Macular Edema
1. Whitcup SM, Csaky KG, Podgor MJ et al. A randomized, masked,
cross-over trial of acetazolamide for cystoid macular edema in
patients with uveitis. Ophthalmology 1996; 103: 1054 -1062;
discussion 1062-1063.
2. Ossewaarde-van Norel A, Rothova A. Clinical review: Update on
treatment of inflammatory macular edema. Ocul Immunol Inflamm. 2011
Feb;19(1):75-83.
Immunosuppression
1. Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of
immunosuppressive drugs in patients with ocular inflammatory
disorders: recommendations of an expert panel. Am J Ophthalmol 2000;
130: 492 -513.
2. Lobo AM, Sobrin L, Papaliodis GN. Drug delivery options for the
treatment of ocular inflammation. Semin Ophthalmol. 2010
Sep-Nov;25(5-6):283-8.
3. Lee SS, Hughes PM, Robinson MR. Recent advances in drug delivery
systems for treating ocular complications of systemic diseases. Curr
Opin Ophthalmol. 2009 Nov;20(6):511-9.
4. Jap A, Chee SP. Immunosuppressive therapy for ocular diseases.
Curr Opin Ophthalmol. 2008 Nov;19(6):535-40.
5. Sugita S. Intravitreal anti-inflammatory treatment for uveitis. Br
J Ophthalmol. 2007 Feb;91(2):135-6.
6. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr
Opin Ophthalmol 2007;18:481-486.
7. Sfikakis PP, Markomichelakis N, Alpsoy E et al. Anti-TNF therapy
in the management of BehVet’s disease –review and basis for
recommendations. Rheumatology 2007;46:736-741.
8. Kempen JH, Daniel E, Gangaputra S et al. Methods for identifying
long-term adverse effects of treatment in patients with eye diseases:
the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort
Study. Ophthalmic Epidemiol 2008;15:47-55.
Investigations and Imaging
1. Singh RP, Young LH. Diagnostic tests for posterior segment
inflammation. Int Ophthalmol Clin. 2006 Spring;46(2):195-208.
2. Herbort CP. Fluorescein and indocyanine green angiography for
uveitis. Middle East Afr J Ophthalmol. 2009 Oct;16(4):168-87.
3. Gallagher MJ, Yilmaz T, Cervantes-Castañeda RA, Foster CS. The
characteristic features of optical coherence tomography in posterior
uveitis. Br J Ophthalmol. 2007 Dec;91(12):1680-5.
XIII. Ocular
Oncology
This list is not exhaustive and the
reading material is recommended and not required.
Textbooks
1. Damato B, Groenewald C. Surgery for intraocular tumors. In:
Bhavsar AR, editor. Retina and vitreous surgery. Philadelphia:
Elsevier; 2009. p. 229-44.
2. Damato B. Ocular tumors: Diagnosis and Treatment. Oxford:
Butterworth Heinemann; 2000.
3. Jager
MJ, Desjardins L, Kivela T, Damato BE. Current Concepts in Uveal
Melanoma. In: Bandello F, editor. Developments in Ophthalmology. Vol
49.
Basel. Karger; 2012
4. Kanski JJ, Milewski SA, Damato BE, Tanner V. Tumors. Diseases of
the ocular fundus. Edinburgh: Elsevier Mosby; 2005. p. 281-325.
5. Ocular oncology. New York: Marcel Dekker; 2003.
6. Ophthalmic oncology. Philadelphia: Saunders; 2005.
7. Ophthalmic pathology and intraocular tumors. San Francisco:
American Academy of Ophthalmology; 2009.
8. Shields JA, Shields CL. Eyelid, conjunctival and orbital tumors.
An atlas and textbook. Second ed. Philadelphia: Lippincott Williams &
Wilkins; 2008.
9. Shields JA, Shields CL. Intraocular tumors. An atlas and textbook.
Second Edition ed. Philadelphia: Lippincott Williams & Wilkins;
2008.
10. Singh AD, Damato BE, Pe'er J, Murphree AL, Perry JD. Clinical
Ophthalmic Oncology. London: Elsevier; 2006.
11. Therapeutic approaches to ocular tumors. In: Spaeth GL, editor.
Ophthalmic Surgery.Philadelphia: Saunders; 2003. p. 699-734.
12. TNM staging of malignant tumors (7th ed). 7th ed. New
York/Berlin: Springer; 2009.
13. Tumors of the retina, choroid, and vitreous. In: Schachat AP,
editor. Retina. 4th ed. Philadelphia: Mosby; 2006. p. 557-872.
14. Tumors. Philadelphia: Lippincott Williams & Wilkins; 2008.
15. Uveal melanoma: a model for exploring fundamental cancer biology.
London: Taylor & Francis; 2004.
16. Zografos L. Tumeurs intraoculaires. Paris: Masson; 2002.
Uveal Melanoma
1. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ,
Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a
predictor for metastatic disease and a potential therapeutic target.
Invest Ophthalmol Vis Sci 2002 January;43(1):1-8.
2. Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe'er J.
The dynamics of serum tumor markers in predicting metastatic uveal
melanoma (part 1). Anticancer Res 2011 January;31(1):345-9.
3. Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de KA.
Oncogenic GNAQ mutations are not correlated with disease-free
survival in uveal melanoma. Br J Cancer 2009 September
1;101(5):813-5.
4. Bechrakis NE, Hocht S, Martus P, Kreusel KM, Heese J, Foerster MH.
[Endoresection following proton beam irradiation of large uveal
melanomas]. Ophthalmologe 2004 April;101(4):370-6.
5. Bechrakis NE, Petousis VE, Willerding G et al. Ten year results of
transscleral resection of large uveal melanomas:Local tumor control
and metastatic rate. Br J Ophthalmol 2009 December 3.
6. Bechrakis NE, Sehu KW, Lee WR, Damato BE, Foerster MH.
Transformation of cell type in uveal melanomas: a quantitative
histologic analysis. Arch Ophthalmol 2000 October;118(10):1406-12.
7. Bedikian AY, Johnson MM, Warneke CL et al. Systemic therapy for
unresectable metastatic melanoma: impact of biochemotherapy on
long-term survival. J Immunotoxicol 2008 April;5(2):201-7.
8. Bergman L, Seregard S, Nilsson B, Lundell G, Ringborg U,
Ragnarsson-Olding B. Uveal melanoma survival in Sweden from 1960 to
1998. Invest Ophthalmol Vis Sci 2003 August;44(8):3282-7.
9. Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers
in uveal melanoma: evidence for a stem cell-like phenotype associated
with metastasis. Melanoma Res 2008 June;18(3):191-200.
10. Char DH, Kroll S, Phillips TL, Quivey JM. Late radiation failures
after iodine 125 brachytherapy for uveal melanoma compared with
charged-particle (proton or helium ion) therapy. Ophthalmology 2002
Oct;109(10):1850-4.
11. Char DH, Miller T, Crawford JB. Eye-wall resection. Trans Am
Ophthalmol Soc 2000;98:153-9; discussion 159-61.:153-9.
12. Char DH, Miller T, Crawford JB. Uveal tumor resection. Br J
Ophthalmol 2001 October;85(10):1213-9.
13. Conway RM, Poothullil AM, Daftari IK, Weinberg V, Chung JE,
O'Brien JM. Estimates of ocular and visual retention following
treatment of extra-large uveal melanomas by proton beam radiotherapy.
Arch Ophthalmol 2006 Jun;124(6):838-43.
14. Cook SA, Damato B, Marshall E, Salmon P. Psychological aspects of
cytogenetic testing of uveal melanoma: preliminary findings and
directions for future research. Eye (Lond) 2009 March;23(3):581-5.
15. Cook SA, Damato B, Marshall E, Salmon P. Psychological aspects of
cytogenetic testing of uveal melanoma: preliminary findings and
directions for future research. Eye 2008 March 14.
16. Cook SA, Damato B, Marshall E, Salmon P. Reconciling the
principle of patient autonomy with the practice of informed consent:
decision-making about prognostication in uveal melanoma. Health
Expect 2010 October 28;10-7625.
17. Coupland SE, Campbell I, Damato B. Routes of Extraocular
Extension of Uveal Melanoma Risk Factors and Influence on Survival
Probability. Ophthalmology 2008 June 11.
18. Damato B, Coupland SE. A reappraisal of the significance of
largest basal diameter of posterior uveal melanoma. Eye (Lond) 2009
December;23(12):2152-60.
19. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452
choroidal melanomas with multiplex ligation-dependent probe
amplification. Clin Cancer Res 2010 December 15;16(24):6083-92.
20. Damato B, Duke C, Coupland SE et al. Cytogenetics of uveal
melanoma: a 7-year clinical experience. Ophthalmology 2007
October;114(10):1925-31.
21. Damato B, Eleuteri A, Fisher AC, Coupland SE, Taktak AF.
Artificial Neural Networks Estimating Survival Probability after
Treatment of Choroidal Melanoma. Ophthalmology 2008 March 13;.
22. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating
prognosis for survival after treatment of choroidal melanoma.Prog
Retin Eye Res. 2011 May 30.
23. Damato B, Groenewald CP, McGalliard JN, Wong D. Rhegmatogenous
retinal detachment after transscleral local resection of choroidal
melanoma. Ophthalmology 2002 November;109(11):2137-43.
24. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton
beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge
experience. Int J Radiat Oncol Biol Phys 2005 Aug 1;62(5):1405-11.
25. Damato B, Kacperek A, Chopra M, Sheen MA, Campbell IR, Errington
RD. Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol
Biol Phys 2005 Sep 1;63(1):109-15.
26. Damato B, Wong D, Green FD, Mackenzie JM. Intrascleral recurrence
of uveal melanoma after transretinal "endoresection". Br J
Ophthalmol 2001 January;85(1):114-5.
27. Damato B. Choroidal melanoma endoresection, dandelions and
allegory-based medicine. Br J Ophthalmol 2008 August;92(8):1013-4.
28. Damato B. Developments in the management of uveal melanoma. Clin
Experiment Ophthalmol 2004 December;32(6):639-47.
29. Damato B. Does ocular treatment of uveal melanoma influence
survival? Br J Cancer 2010 July 27;103(3):285-90.
30. Damato B. Legacy of the collaborative ocular melanoma study. Arch
Ophthalmol 2007 July;125(7):966-8.
31. Dayani PN, Gould JE, Brown DB, Sharma KV, Linette GP, Harbour JW.
Hepatic metastasis from uveal melanoma: angiographic pattern
predictive of survival after hepatic arterial chemoembolization. Arch
Ophthalmol 2009 May;127(5):628-32.
32. De Potter P, Jamart J. Adjuvant indocyanine green in
transpupillary thermotherapy for choroidal melanoma. Ophthalmology
2003 February;110(2):406-13.
33. Demirci H, Shields CL, Shields JA, Eagle RC, Jr., Honavar SG.
Diffuse iris melanoma: a report of 25 cases. Ophthalmology 2002
August;109(8):1553-60.
34. Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C,
Delacroix S, et al. Proton beam radiotherapy for uveal melanoma:
results of Curie Institut-Orsay proton therapy center (ICPO). Int J
Radiat Oncol Biol Phys 2006 Jul 1;65(3):780-7.
35. Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Dendale R,
Delacroix S, Nauraye C, et al. Combined proton beam radiotherapy and
transpupillary thermotherapy for large uveal melanomas: a randomized
study of 151 patients. Ophthalmic Res 2006;38(5):255-60.
36. Dunavoelgyi R, Dieckmann K, Gleiss A et al. Local Tumor Control,
Visual Acuity, and Survival After Hypofractionated Stereotactic
Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated
Between 1997 and 2007. Int J Radiat Oncol Biol Phys 2010 July 31.
37. Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T,
Chamot L, et al. Maximizing local tumor control and survival after
proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol
Phys 2001 Sep 1;51(1):138-47.
38. Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot
L, et al. Eye retention after proton beam radiotherapy for uveal
melanoma. Int J Radiat Oncol Biol Phys 2003 Mar 15;55(4):867-80.
39. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A
prognostic model and staging for metastatic uveal melanoma. Cancer
2003 January 15;97(2):465-75.
40. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T.
Tumor doubling times in metastatic malignant melanoma of the uvea:
tumor progression before and after treatment. Ophthalmology 2000
August;107(8):1443-9.
41. Ferreyra HA, Goldbaum MH, Weinreb RN. Endoresection of irradiated
choroidal melanoma as a treatment for intractable vitreous hemorrhage
and secondary blood-induced glaucoma. Semin Ophthalmol 2008
March;23(2):135-8.
42. Fine SL, Hawkins BS. The investigators' perspective on the
collaborative ocular melanoma study. Arch Ophthalmol 2007
July;125(7):968-71.
43. Frenkel S, Nir I, Hendler K et al. Long-term survival of uveal
melanoma patients after surgery for liver metastases. Br J Ophthalmol
2009 August;93(8):1042-6.
44. Garcia-Arumi J, Balaguer O, Fonollosa A, Boixadera A,
Martinez-Castillo VJ. Endoresection in high posterior choroidal
melanomas: long-term outcome. British Journal of Ophthalmology. In
press 2008.
45. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term
risk of local failure after proton therapy for choroidal/ciliary body
melanoma. Trans Am Ophthalmol Soc 2002;100:43-8; discussion
48-9.:43-8.
46. Gragoudas ES. Proton beam irradiation of uveal melanomas: the
first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci
2006 Nov;47(11):4666-73.
47. Gupta S, Bedikian AY, Ahrar J et al. Hepatic artery
chemoembolization in patients with ocular melanoma metastatic to the
liver: response, survival, and prognostic factors. Am J Clin Oncol
2010 October;33(5):474-80.
48. Hadden PW, Hiscott PS, Damato BE. Histopathology of eyes
enucleated after endoresection of choroidal melanoma. Ophthalmology
2004 January;111(1):154-60.
49. Harbour JW. Molecular prognostic testing and individualized
patient care in uveal melanoma. Am J Ophthalmol 2009
December;148(6):823-9.
50. Hawkins BS. The Collaborative Ocular Melanoma Study (COMS)
randomized trial of pre-enucleation radiation of large choroidal
melanoma: IV. Ten-year mortality findings and prognostic factors.
COMS report number 24. Am J Ophthalmol 2004 December;138(6):936-51.
51. Huppert PE, Fierlbeck G, Pereira P et al. Transarterial
chemoembolization of liver metastases in patients with uveal
melanoma. Eur J Radiol 2009 May.
52. Isager P, Engholm G, Overgaard J, Storm H. Uveal and conjunctival
malignant melanoma in denmark 1943-97: observed and relative survival
of patients followed through 2002. Ophthalmic Epidemiol 2006
April;13(2):85-96.
53. Karkhaneh R, Chams H, Amoli FA et al. Long-term surgical outcome
of posterior choroidal melanoma treated by endoresection. Retina 2007
September;27(7):908-14.
54. Kennedy AS, Nutting C, Jakobs T et al. A first report of
radioembolization for hepatic metastases from ocular melanoma. Cancer
Invest 2009 July;27(6):682-90.
55. Kim IK, Lane AM, Egan KM, Munzenrider J, Gragoudas ES. Natural
history of radiation papillopathy after proton beam irradiation of
parapapillary melanoma. Ophthalmology 2010 Aug;117(8):1617-22.
56. Kim JW, Damato BE, Hiscott P. Noncontiguous tumor recurrence of
posterior uveal melanoma after transscleral local resection. Arch
Ophthalmol 2002 December;120(12):1659-64.
57. Kujala E, Makitie T, Kivela T. Very long-term prognosis of
patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci
2003 November;44(11):4651-9.
58. Lake SL, Coupland SE, Taktak AF, Damato BE. Whole genome
microarray detects deletions and loss of heterozygosity of chromosome
3 occurring exclusively in metastasizing uveal melanoma. Invest
Ophthalmol Vis Sci 2010 May 5.
59. Lane AM, Egan KM, Harmon D, Holbrook A, Munzenrider JE, Gragoudas
ES. Adjuvant Interferon Therapy for Patients with Uveal Melanoma at
High Risk of Metastasis. Ophthalmology 2009 November;116(11):2206-12.
60. Lane AM, Egan KM, Kim IK, Gragoudas ES. Mortality after diagnosis
of small melanocytic lesions of the choroid. Arch Ophthalmol 2010
August;128(8):996-1000.
61. Langmann G, Pendl G, Klaus-Mulln e, Papaefthymiou G, Guss H.
Gamma knife radiosurgery for uveal melanomas: an 8-year experience. J
Neurosurg 2000 December;93 Suppl 3:184-8:184-8.
62. Langmann G, Pendl G, Mullner K, Feichtinger KH, Papaefthymiouaf
G. High-compared with low-dose radiosurgery for uveal melanomas. J
Neurosurg 2002 December;97(5 Suppl):640-3.
63. Lumbroso-Le Rouic L, Delacroix S, Dendale R, Levy-Gabriel C,
Feuvret L, Noel G, et al. Proton beam therapy for iris melanomas. Eye
2006 Nov;20(11):1300-5.
64. Maat W, Haasnoot GW, Claas FH, Schalij-Delfos NE, Schreuder GM,
Jager MJ. HLA Class I and II genotype in uveal melanoma: relation to
occurrence and prognosis. Invest Ophthalmol Vis Sci 2006
January;47(1):3-6.
65. Maat W, Jordanova ES, van Zelderen-Bhola SL et al. The
heterogeneous distribution of monosomy 3 in uveal melanomas:
implications for prognostication based on fine-needle aspiration
biopsies. Arch Pathol Lab Med 2007 January;131(1):91-6.
66. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos
NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype
occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008
February;49(2):505-10.
67. Mariani P, Piperno-Neumann S, Servois V et al. Surgical
management of liver metastases from uveal melanoma: 16 years'
experience at the Institut Curie. Eur J Surg Oncol 2009
November;35(11):1192-7.
68. Marucci L, Ancukiewicz M, Lane AM, Collier JM, Gragoudas ES,
Munzenrider JE. Uveal melanoma recurrence after fractionated proton
beam therapy: comparison of survival in patients treated with
reirradiation or with enucleation. Int J Radiat Oncol Biol Phys 2011
Mar 1;79(3):842-6.
69. Marucci L, Ancukiewicz M, Lane AM, Collier JM, Gragoudas ES,
Munzenrider JE. Uveal melanoma recurrence after fractionated proton
beam therapy: comparison of survival in patients treated with
reirradiation or with enucleation. Int J Radiat Oncol Biol Phys 2011
March 1;79(3):842-6.
70. Mashayekhi A, Shields CL, Lee SC, Marr BP, Shields JA. Retinal
break and rhegmatogenous retinal detachment after transpupillary
thermotherapy as primary or adjunct treatment of choroidal melanoma.
Retina 2008 February;28(2):274-81.
71. Mensink HW, Vaarwater J, de Keizer RJ et al. Chromosomal
aberrations in iris melanomas. Br J Ophthalmol 2011
March;95(3):424-8.
72. Mensink HW, Vaarwater J, Kilic E et al. Chromosome 3 intratumor
heterogeneity in uveal melanoma. Invest Ophthalmol Vis Sci 2009
February;50(2):500-4.
73. Mittica N, Vemuganti GK, Duffy M, Torczynski E, Edward DP. Late
orbital recurrence of a choroidal melanoma following internal
resection: report of a case and review of the literature. Surv
Ophthalmol 2003 March;48(2):181-90.
74. Modorati G, Miserocchi E, Galli L, Picozzi P, Rama P. Gamma knife
radiosurgery for uveal melanoma: 12 years of experience. Br J
Ophthalmol 2009 January;93(1):40-4.
75. Mueller AJ, Talies S, Schaller UC, Horstmann G, Wowra B, Kampik
A. Stereotactic radiosurgery of large uveal melanomas with the
gamma-knife. Ophthalmology 2000 July;107(7):1381-7.
76. Murthy R, Honavar SG, Naik M, Reddy VA, Vemuganti GK.
Clinicopathologic findings in choroidal melanomas after failed
transpupillary thermotherapy. Am J Ophthalmol 2004
March;137(3):594-5.
77. Parrozzani R, Boccassini B, de B, V, Radin PP, Midena E.
Long-term outcome of transpupillary thermotherapy as primary
treatment of selected choroidal melanoma. Acta Ophthalmol 2009
November;87(7):789-92.
78. Rivoire M, Kodjikian L, Negrier S. Prolonged survival after
complete resection of metastases from intraocular melanoma. Cancer
2004 July 1;101(1):207-8.
79. Rundle P, Singh AD, Rennie I. Proton beam therapy for iris
melanoma: a review of 15 cases. Eye 2007 Jan;21(1):79-82.
80. Schilling H, Bornfeld N, Talies S et al. [Endoresection of large
uveal melanomas after pretreatment by single-dose stereotactic
convergence irradiation with the leksell gamma knife--first
experience on 46 cases]. Klin Monatsbl Augenheilkd 2006
June;223(6):513-20.
81. Servois V, Mariani P, Malhaire C et al. Preoperative staging of
liver metastases from uveal melanoma by magnetic resonance imaging
(MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
Eur J Surg Oncol 2010 February;36(2):189-94.
82. Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A,
Shields JA. Prognosis of uveal melanoma in 500 cases using genetic
testing of fine-needle aspiration biopsy specimens. Ophthalmology
2011 February;118(2):396-401.
83. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary
transpupillary thermotherapy for small choroidal melanoma in 256
consecutive cases: outcomes and limitations. Ophthalmology 2002
February;109(2):225-34.
84. Singh AD, Eagle RC, Jr., Shields CL, Shields JA.
Clinicopathologic reports, case reports, and small case series:
enucleation following transpupillary thermotherapy of choroidal
melanoma: clinicopathologic correlations. Arch Ophthalmol 2003
March;121(3):397-400.
85. Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The
Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol
2004 July;88(7):962-7.
86. Singh AD, Rundle PA, Berry-Brincat A, Parsons MA, Rennie IG.
Extrascleral extension of choroidal malignant melanoma following
transpupillary thermotherapy. Eye 2004 January;18(1):91-3.
87. Starr OD, Patel DV, Allen JP, McGhee CN. Iris melanoma:
pathology, prognosis and surgical intervention. Clin Experiment
Ophthalmol 2004 June;32(3):294-6.
88. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE. Mortality
after deferral of treatment or no treatment for choroidal melanoma.
Am J Ophthalmol 2003 July;136(1):47-54.
89. The COMS randomized trial of iodine 125 brachytherapy for
choroidal melanoma: V. Twelve-year mortality rates and prognostic
factors: COMS report No. 28. Arch Ophthalmol 2006
December;124(12):1684-93.
90. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and
tumor-infiltrating macrophages in choroidal and ciliary body melanoma
and corresponding metastases. Invest Ophthalmol Vis Sci 2004
January;45(1):1-6.
91. Toktas ZO, Bicer A, Demirci G et al. Gamma knife stereotactic
radiosurgery yields good long-term outcomes for low-volume uveal
melanomas without intraocular complications. J Clin Neurosci 2010
April;17(4):441-5.
92. Torres V, Triozzi P, Eng C et al. Circulating tumor cells in
uveal melanoma. Future Oncol 2011 January;7(1):101-9.
93. Tsai T, O'Brien JM, Engstrom R, Straatsma BR. Extrascleral
extension of a choroidal melanoma after argon photocoagulation and
transpupillary thermotherapy. Br J Ophthalmol 2002 March;86(3):358-9.
94. Yamamoto A, Chervoneva I, Sullivan KL et al. High-dose
immunoembolization: survival benefit in patients with hepatic
metastases from uveal melanoma. Radiology 2009 July;252(1):290-8.
95. Yeung SN, Paton KE, Waite C, Maberley DA. Intravitreal
bevacizumab for iris neovascularization following proton beam
irradiation for choroidal melanoma. Can J Ophthalmol 2010
Jun;45(3):269-73.
Retinoblastoma
1. Abouzeid H, Moeckli R, Gaillard MC et al. (106)Ruthenium
brachytherapy for retinoblastoma. Int J Radiat Oncol Biol Phys 2008
July 1;71(3):821-8.
2. Abouzeid H, Schorderet DF, Balmer A, Munier FL. Germline mutations
in retinoma patients: relevance to low-penetrance and
low-expressivity molecular basis. Mol Vis 2009;15:771-7. Epub;%2009
Apr 17.:771-7.
3. Ali MJ, Reddy VA, Honavar SG, Naik M. Orbital retinoblastoma:
Where do we go from here? J Cancer Res Ther 2011 January;7(1):11-4.
4. Brisse HJ, Guesmi M, Aerts I et al. Relevance of CT and MRI in
retinoblastoma for the diagnosis of postlaminar invasion with
normal-size optic nerve: a retrospective study of 150 patients with
histological comparison. Pediatr Radiol 2007 July;37(7):649-56.
5. Bunin GR, Felice MA, Davidson W et al. Medical radiation exposure
and risk of retinoblastoma resulting from new germline RB1 mutation.
Int J Cancer 2011 May 1;128(10):2393-404.
6. Chantada, G., F. Doz, et al. (2006). "A proposal for an
international retinoblastoma staging system." Pediatr Blood
Cancer 47(6): 801-805.
7. de Graaf, P., S. Goricke, et al. (2011). "Guidelines for
imaging retinoblastoma: imaging principles and MRI standardization."
Pediatr Radiol.Dunkel IJ, Chan HS, Jubran R et al. High-dose
chemotherapy with autologous hematopoietic stem cell rescue for stage
4B retinoblastoma. Pediatr Blood Cancer 2010 July 15;55(1):149-52.
8. Dunkel IJ, Jubran RF, Gururangan S et al. Trilateral
retinoblastoma: potentially curable with intensive chemotherapy.
Pediatr Blood Cancer 2010 March;54(3):384-7.
9. Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary
retinoblastoma associated with primary ectopic intracranial
retinoblastoma. J Clin Oncol 1999 June;17(6):1829-37.
10. Kivela T. 200 years of success initiated by James Wardrop's 1809
monograph on retinoblastoma. Acta Ophthalmol 2009
November;87(8):810-2.
11. Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE,
Fraumeni JF, Jr. Risk of soft tissue sarcomas by individual subtype
in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007
January 3;99(1):24-31.
12. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev
Cancer 2001 November;1(2):157-62.
13. Levy J, Frenkel S, Baras M, Neufeld M, Pe'er J. Calcification in
retinoblastoma: histopathologic findings and statistical analysis of
302 cases. Br J Ophthalmol 2011 January 27.
14. Lin P, O'Brien JM. Frontiers in the management of retinoblastoma.
Am J Ophthalmol 2009 August;148(2):192-8.
15. Linn Murphree, A. (2005). "Intraocular retinoblastoma: the
case for a new group classification." Ophthalmol Clin North Am
18(1): 41-53.
16. Lohmann D. Retinoblastoma. Adv Exp Med Biol
2010;685:220-7.:220-7.
17. Lohmann DR, Gallie BL, Gobin YP et al. Retinoblastoma
18. Lumbroso-Le RL, Aerts I, Levy-Gabriel C et al. Conservative
treatments of intraocular retinoblastoma. Ophthalmology 2008
August;115(8):1405-10, 1410.
19. Munier FL, Verwey J, Pica A et al. New developments in external
beam radiotherapy for retinoblastoma: from lens to normal
tissue-sparing techniques. Clin Experiment Ophthalmol 2008
January;36(1):78-89.
20. Osman IM, Abouzeid H, Balmer A et al. Modern cataract surgery for
radiation-induced cataracts in retinoblastoma. Br J Ophthalmol 2011
February;95(2):227-30.
21. Pogrzebielski A, Shields CL, Romanowska-Dixon B, Shields JA.
[Retinoblastoma update--management and classification (Part I)]. Klin
Oczna 2006;108(4-6):253-7.
22. Pogrzebielski A, Shields CL, Romanowska-Dixon B, Shields JA.
[Retinoblastoma update--therapy (Part II)]. Klin Oczna
2006;108(4-6):258-62.
23. Rodriguez-Galindo C, Wilson MW, Chantada G et al. Retinoblastoma:
one world, one vision. Pediatrics 2008 September;122(3):e763-e770.
24. Sastre, X., G. L. Chantada, et al. (2009). "Proceedings of
the consensus meetings from the International Retinoblastoma Staging
Working Group on the pathology guidelines for the examination of
enucleated eyes and evaluation of prognostic risk factors in
retinoblastoma." Arch Pathol Lab Med 133(8): 1199-1202.
25. Schefler AC, Abramson DH. Retinoblastoma: what is new in
2007-2008. Curr Opin Ophthalmol 2008 November;19(6):526-34.
26. Shields CL, Ghassemi F, Tuncer S, Thangappan A, Shields JA.
Clinical spectrum of diffuse infiltrating retinoblastoma in 34
consecutive eyes. Ophthalmology 2008 December;115(12):2253-8.
27. Shields CL, Shields JA. Retinoblastoma management: advances in
enucleation, intravenous chemoreduction, and intra-arterial
chemotherapy. Curr Opin Ophthalmol 2010 May;21(3):203-12.
28. Shields CL, Shields JA. Basic understanding of current
classification and management of retinoblastoma. Curr Opin Ophthalmol
2006 June;17(3):228-34.
29. Vahedi A, Lumbroso-Le RL, Levy GC et al. [Differential diagnosis
of retinoblastoma: a retrospective study of 486 cases]. J Fr
Ophtalmol 2008 February;31(2):165-72.
30. Zage PE, Reitman AJ, Seshadri R et al. Outcomes of a two-drug
chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood
Cancer 2008 March;50(3):567-72.
Other Intraocular Tumors
1. Aizman A, Finger PT, Shabto U, Szechter A, Berson A. Palladium 103
(103Pd) plaque radiation therapy for circumscribed choroidal
hemangioma with retinal detachment. Arch Ophthalmol 2004
November;122(11):1652-6.
2. Ascaso FJ, Villen L. Fundus Autofluorescence Imaging Findings in
Choroidal Osteoma. Retina 2011 April 9.
3. Augsburger JJ, Henson GL, Hershberger VS, Trichopoulos N.
Topographical distribution of typical unifocal congenital hypertrophy
of retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol 2006
November;244(11):1412-4.
4. Bianciotto C, Shields CL, Lally SE, Freire J, Shields JA.
CyberKnife radiosurgery for the treatment of intraocular and
periocular lymphoma. Arch Ophthalmol 2010 December;128(12):1561-7.
5. Cassoux N, Giron A, Bodaghi B et al. IL-10 measurement in aqueous
humor for screening patients with suspicion of primary intraocular
lymphoma. Invest Ophthalmol Vis Sci 2007 July;48(7):3253-9.
6. Chan CC, Fisson S, Bodaghi B. The future of primary intraocular
lymphoma (retinal lymphoma). Ocul Immunol Inflamm 2009
November;17(6):375-9.
7. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv
Ophthalmol 2003 January;48(1):12-38.
8. Chan RP, Lai TY. Photodynamic therapy with verteporfin for
vasoproliferative tumor of the retina. Acta Ophthalmol 2010
September;88(6):711-2.
9. Chan RV, Yonekawa Y, Lane AM et al. Proton beam irradiation using
a light-field technique for the treatment of choroidal hemangiomas.
Ophthalmologica 2010;224(4):209-16.
10. Chen J, Lee L, Gass JD. Choroidal osteoma: evidence of
progression and decalcification over 20 years. Clin Exp Optom 2006
March;89(2):90-4.
11. Cohen VM, Shields CL, Demirci H, Shields JA. Iodine I 125 plaque
radiotherapy for vasoproliferative tumors of the retina in 30 eyes.
Arch Ophthalmol 2008 September;126(9):1245-51.
12. Coupland SE, Chan CC, Smith J. Pathophysiology of retinal
lymphoma. Ocul Immunol Inflamm 2009 July;17(4):227-37.
13. Coupland SE, Damato B. Lymphomas involving the eye and the ocular
adnexa. Curr Opin Ophthalmol 2006 December;17(6):523-31.
14. Coupland SE, Damato B. Understanding intraocular lymphomas. Clin
Experiment Ophthalmol 2008 August;36(6):564-78.
15. Coupland SE, Hummel M, Muller HH, Stein H. Molecular analysis of
immunoglobulin genes in primary intraocular lymphoma. Invest
Ophthalmol Vis Sci 2005 October;46(10):3507-14.
16. Damato B. Vasoproliferative retinal tumor. Br J Ophthalmol 2006
April;90(4):399-400.
17. De SG, Krebs I, Binder S. High-definition optical coherence
tomography in a case of congenital hypertrophy of the retinal pigment
epithelium. Ophthalmic Surg Lasers Imaging 2010 November;41
Suppl:S93-5. doi: 10.3928/15428877-20101031-04.:S93-S95.
18. Demirci H, Shields CL, Chao AN, Shields JA. Uveal metastasis from
breast cancer in 264 patients. Am J Ophthalmol 2003
August;136(2):264-71.
19. Eagle RC, Jr., Shields JA, Shields CL, Wood MG. Hamartomas of the
iris and ciliary epithelium in tuberous sclerosis complex. Arch
Ophthalmol 2000 May;118(5):711-5.
20. Esmaili DD, Mukai S, Jakobiec FA, Kim IK, Gragoudas ES. Ocular
melanocytoma. Int Ophthalmol Clin 2009;49(1):165-75.
21. Frenkel S, Hendler K, Siegal T, Shalom E, Pe'er J. Intravitreal
methotrexate for treating vitreoretinal lymphoma: 10 years of
experience. Br J Ophthalmol 2008 March;92(3):383-8.
22. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J
Gastroenterol 2006 February;101(2):385-98.
23. Goldberg S, Frenkel S, Blumenthal EZ, Solomon A, Pe'er J.
Intraocular lymphoma. Ophthalmology 2007 June;114(6):1236-7.
24. Grant LW, Anderson C, Macklis RM, Singh AD. Low dose irradiation
for diffuse choroidal hemangioma. Ophthalmic Genet 2008
December;29(4):186-8.
25. Grenga PL, Sagoo MS, Malagola R. Recurrent vitreous haemorrhage
from sporadic retinal astrocytic hamartoma. Eye (Lond) 2007
May;21(5):682-4.
26. Grimm SA, McCannel CA, Omuro AM et al. Primary CNS lymphoma with
intraocular involvement: International PCNSL Collaborative Group
Report. Neurology 2008 October 21;71(17):1355-60.
27. Grimm SA, Pulido JS, Jahnke K et al. Primary intraocular
lymphoma: an International Primary Central Nervous System Lymphoma
Collaborative Group Report. Ann Oncol 2007 November;18(11):1851-5.
28. Heimann H, Damato B. Congenital vascular malformations of the
retina and choroid. Eye (Lond) 2010 March;24(3):459-67.
29. Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina
2009 February;29(2):129-32.
30. Jahnke K, Korfel A, Komm J et al. Intraocular lymphoma 2000-2005:
results of a retrospective multicentre trial. Graefes Arch Clin Exp
Ophthalmol 2006 June;244(6):663-9.
31. Karp CL, Galor A, Chhabra S, Barnes SD, Alfonso EC.
Subconjunctival/perilesional recombinant interferon alpha2b for
ocular surface squamous neoplasia: a 10-year review. Ophthalmology
2010 December;117(12):2241-6.
32. Kenawy N, Groenwald C, Damato B. Treatment of a vasoproliferative
tumor with intravitreal bevacizumab (Avastin). Eye (Lond) 2007
June;21(6):893-4.
33. Kitzmann AS, Pulido JS, Ferber MJ, Highsmith WE,
Babovic-Vuksanovic D. A splice-site mutation in CCM1/KRIT1 is
associated with retinal and cerebral cavernous hemangioma. Ophthalmic
Genet 2006 December;27(4):157-9.
34. Kitzmann AS, Pulido JS, Mohney BG et al. Intraocular use of
rituximab. Eye (Lond) 2007 December;21(12):1524-7.
35. Kong DS, Lee JI, Kang SW. Gamma knife radiosurgery for choroidal
hemangioma. Am J Ophthalmol 2007 August;144(2):319-22.
36. Krohn J, Froystein T, Dahl O. Topography of solitary congenital
hypertrophy of the retinal pigment epithelium in the ocular fundus.
Acta Ophthalmol 2009 November;87(8):921-2.
37. Kwan AS, Ramkissoon YD, Gregor ZJ. Surgical management of retinal
capillary hemangioblastoma associated with retinal detachment. Retina
2008 October;28(8):1159-62.
38. Labauge P, Krivosic V, Denier C, Tournier-Lasserve E, Gaudric A.
Frequency of retinal cavernomas in 60 patients with familial cerebral
cavernomas: a clinical and genetic study. Arch Ophthalmol 2006
June;124(6):885-6.
39. Lazzeri S, Figus M, Di BE, Rizzo S, Nardi M. Verteporfin
photodynamic therapy for retinal hemangioblastoma associated with Von
Hippel-Lindau disease in a 9-year-old child. Clin Experiment
Ophthalmol 2011 March;39(2):179-81.
40. Lee BJ, Lowder CY, Biscotti C, Schoenfield L, Singh AD. Ciliary
body metastasis masquerading as scleritis. Br J Ophthalmol 2007
December;91(12):1582, 1649.
41. Levy-Gabriel C, Rouic LL, Plancher C et al. Long-term results of
low-dose proton beam therapy for circumscribed choroidal hemangiomas.
Retina 2009 February;29(2):170-5.
42. Leys AM, Silva R, Inhoffen W, Tatar O. Neovascular growth
following photodynamic therapy for choroidal hemangioma and
neovascular regression after intravitreous injection of
triamcinolone. Retina 2006 July;26(6):693-7.
43. Lindegaard J, Heegaard S, Toft PB, Nysom K, Prause JU. Malignant
transformation of a medulloepithelioma of the optic nerve. Orbit 2010
June;29(3):161-4.
44. Lu Y, Jia L, He S et al. Melanoma-associated retinopathy: a
paraneoplastic autoimmune complication. Arch Ophthalmol 2009
December;127(12):1572-80.
45. Meunier J, Lumbroso-Le RL, Vincent-Salomon A et al.
Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single
centre study of initial characteristics, natural history, and
prognostic factors. Hematol Oncol 2004 December;22(4):143-58.
46. Mochizuki M, Singh AD. Epidemiology and clinical features of
intraocular lymphoma. Ocul Immunol Inflamm 2009 March;17(2):69-72.
47. Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M.
International Central Nervous System and Ocular Lymphoma Workshop:
recommendations for the future. Ocul Immunol Inflamm 2006
June;14(3):139-44.
48. Parsons MA, Rennie IG, Rundle PA, Dhingra S, Mudhar H, Singh AD.
Congenital hypertrophy of retinal pigment epithelium: a
clinico-pathological case report. Br J Ophthalmol 2005
July;89(7):920-1.
49. Patikulsila D, Visaetsilpanonta S, Sinclair SH, Shields JA.
Cavernous hemangioma of the optic disk. Retina 2007
March;27(3):391-2.
50. Pe'er J, Hochberg FH, Foster CS. Clinical review: treatment of
vitreoretinal lymphoma. Ocul Immunol Inflamm 2009
September;17(5):299-306.
51. Powell SF, Dudek AZ. Treatment of melanoma-associated
retinopathy. Curr Treat Options Neurol 2010 January;12(1):54-63.
52. Rajagopal R, Harbour JW. Diagnostic testing and treatment choices
in primary vitreoretinal lymphoma. Retina 2011 March;31(3):435-40.
53. Ramaesh K, Marshall JW, Wharton SB, Dhillon B. Intraocular
metastases of cutaneous malignant melanoma: a case report and review
of the literature. Eye (Lond) 1999 April;13(Pt 2):247-50.
54. Ramasubramanian A, Shields CL, Harmon SA, Shields JA.
Autofluorescence of choroidal hemangioma in 34 consecutive eyes.
Retina 2010 January;30(1):16-22.
55. Raparia K, Chang CC, Chevez-Barrios P. Intraocular lymphoma:
diagnostic approach and immunophenotypic findings in vitrectomy
specimens. Arch Pathol Lab Med 2009 August;133(8):1233-7.
56. Rennie IG. Retinal vasoproliferative tumors. Eye (Lond) 2010
March;24(3):468-71.
57. Saldanha MJ, Edrich C. Treatment of vasoproliferative tumors with
photodynamic therapy. Ophthalmic Surg Lasers Imaging 2008
March;39(2):143-5.
58. Sasmal NK, Mandal R, Biswas MC, Ghosh A, Mitra A, Boler AK. Iris
naevus (Cogan-Reese) syndrome. J Indian Med Assoc 2008
August;106(8):538.
59. Sen HN, Bodaghi B, Hoang PL, Nussenblatt R. Primary intraocular
lymphoma: diagnosis and differential diagnosis. Ocul Immunol Inflamm
2009 May;17(3):133-41.
60. Sen J, Clewes AR, Quah SA, Hiscott PS, Bucknall RC, Damato BE.
Presymptomatic diagnosis of bronchogenic carcinoma associated with
bilateral diffuse uveal melanocytic proliferation. Clin Experiment
Ophthalmol 2006 March;34(2):156-8.
61. Sharma P, Shields CL, Turaka K, Eagle RC, Jr., Shields JA.
Ciliary body medulloepithelioma with neoplastic cyclitic membrane
imaging with fluorescein angiography and ultrasound biomicroscopy.
Graefes Arch Clin Exp Ophthalmol 2011 April;%20.
62. Shields CL, Benevides R, Materin MA, Shields JA. Optical
coherence tomography of retinal astrocytic hamartoma in 15 cases.
Ophthalmology 2006 September;113(9):1553-7.
63. Shields CL, Mashayekhi A, Ho T, Cater J, Shields JA. Solitary
congenital hypertrophy of the retinal pigment epithelium: clinical
features and frequency of enlargement in 330 patients. Ophthalmology
2003 October;110(10):1968-76.
64. Shields CL, Materin MA, Mehta S, Foxman BT, Shields JA.
Regression of extrafoveal choroidal osteoma following photodynamic
therapy. Arch Ophthalmol 2008 January;126(1):135-7.
65. Shields CL, Pirondini C, Bianciotto C, Harmon SA, Shields JA.
Autofluorescence of congenital hypertrophy of the retinal pigment
epithelium. Retina 2007 October;27(8):1097-100.
66. Shields CL, Sun H, Demirci H, Shields JA. Factors predictive of
tumor growth, tumor decalcification, choroidal neovascularization,
and visual outcome in 74 eyes with choroidal osteoma. Arch Ophthalmol
2005 December;123(12):1658-66.
67. Shields CL, Thangappan A, Hartzell K, Valente P, Pirondini C,
Shields JA. Combined hamartoma of the retina and retinal pigment
epithelium in 77 consecutive patients visual outcome based on macular
versus extramacular tumor location. Ophthalmology 2008
December;115(12):2246-52.
68. Shields JA, Eagle RC, Jr., Shields CL, Brown GC, Lally SE.
Malignant transformation of congenital hypertrophy of the retinal
pigment epithelium. Ophthalmology 2009 November;116(11):2213-6.
69. Shields JA, Mashayekhi A, Ra S, Shields CL. Pseudomelanomas of
the posterior uveal tract: the 2006 Taylor R. Smith Lecture. Retina
2005 September;25(6):767-71.
70. Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S. Von
Hippel-Lindau disease: molecular pathological basis, clinical
criteria, genetic testing, clinical features of tumors and treatment.
Jpn J Clin Oncol 2006 June;36(6):337-43.
71. Singh AD, Kaiser PK, Sears JE. Choroidal hemangioma. Ophthalmol
Clin North Am 2005 March;18(1):151-61, ix.
72. Song WK, Byeon SH, Kim SS, Kwon OW, Lee SC. Gamma knife
radiosurgery for choroidal haemangiomas with extensive exudative
retinal detachment. Br J Ophthalmol 2009 June;93(6):836-7.
73. Song WK, Koh HJ, Kwon OW, Byeon SH, Lee SC. Intravitreal
bevacizumab for choroidal neovascularization secondary to choroidal
osteoma. Acta Ophthalmol 2009 February;87(1):100-1.
74. Soysal HG. Metastatic tumors of the uvea in 38 eyes. Can J
Ophthalmol 2007 December;42(6):832-5.
75. Swann PG. Iris mammillations in ocular melanocytosis. Clin Exp
Optom 2001 January;84(1):35-8.
76. Taban M, Sears JE, Singh AD. Ciliary body naevus. Eye (Lond) 2007
December;21(12):1528-30.
77. Torres VL, Brugnoni N, Kaiser PK, Singh AD. Optical coherence
tomography enhanced depth imaging of choroidal tumors. Am J
Ophthalmol 2011 April;151(4):586-93.
78. Trichopoulos N, Augsburger JJ. Neuroendocrine tumors metastatic
to the uvea: diagnosis by fine needle aspiration biopsy. Graefes Arch
Clin Exp Ophthalmol 2006 April;244(4):524-8.
79. Tsipursky MS, Golchet PR, Jampol LM. Photodynamic therapy of
choroidal hemangioma in sturge-weber syndrome, with a review of
treatments for diffuse and circumscribed choroidal hemangiomas. Surv
Ophthalmol 2011 January;56(1):68-85.
80. Turell ME, Singh AD. Vascular tumors of the retina and choroid:
diagnosis and treatment. Middle East Afr J Ophthalmol 2010
July;17(3):191-200.
81. Vrabec TR, Augsburger JJ. Exudative retinal detachment due to
small noncalcified retinal astrocytic hamartoma. Am J Ophthalmol 2003
November;136(5):952-4.
82. Wackernagel W, Lackner EM, Pilz S, Mayer C, Stepan V. von
Hippel-Lindau disease: treatment of retinal haemangioblastomas by
targeted therapy with systemic bevacizumab. Acta Ophthalmol 2010
November;88(7):e271-e272.
83. Wong WT, Agron E, Coleman HR et al. Clinical characterization of
retinal capillary hemangioblastomas in a large population of patients
with von Hippel-Lindau disease. Ophthalmology 2008
January;115(1):181-8.
84. Wong WT, Liang KJ, Hammel K, Coleman HR, Chew EY. Intravitreal
ranibizumab therapy for retinal capillary hemangioblastoma related to
von Hippel-Lindau disease. Ophthalmology 2008
November;115(11):1957-64.
85. Yeh S, Weichel ED, Faia LJ et al. 25-Gauge transconjunctival
sutureless vitrectomy for the diagnosis of intraocular lymphoma. Br J
Ophthalmol 2010 May;94(5):633-8.
86. Zhang X, Dong F, Dai R, Yu W. Surgical management of epiretinal
membrane in combined hamartomas of the retina and retinal pigment
epithelium. Retina 2010 February;30(2):305-9.
Melanocytic Conjunctival Lesions
1. Ackerman AB, Sood R, Koenig M. Primary acquired melanosis of the
conjunctiva is melanoma in situ. Mod Pathol 1991 March;4(2):253-63.
2. Anandajeya WV, Correa ZM, Augsburger JJ. Primary acquired
melanosis with atypia treated with mitomycin C. Int Ophthalmol 2009
August;29(4):285-8.
3. Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N,
Steuhl KP. Prognostic value of clinical and histopathological
parameters in conjunctival melanomas: a retrospective study. Br J
Ophthalmol 2002 February;86(2):163-7.
4. Busam KJ, Fang Y, Jhanwar SC, Pulitzer MP, Marr B, Abramson DH.
Distinction of conjunctival melanocytic nevi from melanomas by
fluorescence in situ hybridization. J Cutan Pathol 2010
February;37(2):196-203.
5. Dalla PG, Ghirlando A, Busato F, Midena E. Reconstruction of
conjunctiva with amniotic membrane after excision of large
conjunctival melanoma: a long-term study. Eur J Ophthalmol 2005
July;15(4):446-50.
6. Damato B, Coupland SE. Conjunctival melanoma and melanosis: a
reappraisal of terminology, classification and staging. Clin
Experiment Ophthalmol 2008 November;36(8):786-95.
7. Damato B, Coupland SE. An audit of conjunctival melanoma treatment
in Liverpool. Eye (Lond) 2009 April;23(4):801-9.
8. Damato B, Coupland SE. Management of conjunctival melanoma. Expert
Rev Anticancer Ther 2009 September;9(9):1227-39.
9. Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy
for conjunctival malignant melanoma and primary acquired melanosis
with atypia: clinical experience with histopathologic observations.
Arch Ophthalmol 2000 July;118(7):885-91.
10. Demirci H, Shields CL, Bianciotto CG, Shields JA. Topical
imiquimod for periocular lentigo maligna. Ophthalmology 2010
December;117(12):2424-9.
11. Desjardins L, Poncet P, Levy C, Schlienger P, Asselain B,
Validire P. [Prognostic factors in malignant melanoma of the
conjunctiva. An anatomo-clinical study of 56 patients]. J Fr
Ophtalmol 1999 April;22(3):315-21.
12. Dratviman-Storobinsky O, Cohen Y, Frenkel S, Pe'er J,
Goldenberg-Cohen N. Lack of oncogenic GNAQ mutations in melanocytic
lesions of the conjunctiva as compared to uveal melanoma. Invest
Ophthalmol Vis Sci 2010 December;51(12):6180-2.
13. Folberg R, McLean IW, Zimmerman LE. Conjunctival melanosis and
melanoma. Ophthalmology 1984 June;91(6):673-8.
14. Folberg R, McLean IW, Zimmerman LE. Malignant melanoma of the
conjunctiva. Hum Pathol 1985 February;16(2):136-43.
15. Fuchs U, Kivela T, Liesto K, Tarkkanen A. Prognosis of
conjunctival melanomas in relation to histopathological features. Br
J Cancer 1989 February;59(2):261-7.
16. Goldenberg-Cohen N, Cohen Y, Rosenbaum E et al. T1799A BRAF
mutations in conjunctival melanocytic lesions. Invest Ophthalmol Vis
Sci 2005 September;46(9):3027-30.
17. Groh MJ, Holbach LM, Kuhnel B, Conway RM, Naumann GO. [Management
of conjunctival malignant melanoma associated with primary acquired
melanosis (PAM) using 0.02% mitomycin C eyedrops]. Ophthalmologe 2003
September;100(9):708-12.
18. Harooni H, Schoenfield LR, Singh AD. Current appraisal of
conjunctival melanocytic tumors: classification and treatment. Future
Oncol 2011 March;7(3):435-46.
19. Heegaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis
of malignant melanoma of the conjunctiva and uvea: comparison of the
novel antibody against melan-A with S100 protein and HMB-45. Melanoma
Res 2000 August;10(4):350-4.
20. Jakobiec FA. The ultrastructure of conjunctival melanocytic
tumors. Trans Am Ophthalmol Soc 1984;82:599-752.:599-752.
21. Jay V, Font RL. Conjunctival amelanotic malignant melanoma
arising in primary acquired melanosis sine pigmento. Ophthalmology
1998 January;105(1):191-4.
22. Kim JW, Abramson DH. Topical treatment options for conjunctival
neoplasms. Clin Ophthalmol 2008 September;2(3):503-15.
23. Lichtinger A, Pe'er J, Frucht-Pery J, Solomon A. Limbal stem cell
deficiency after topical mitomycin C therapy for primary acquired
melanosis with atypia. Ophthalmology 2010 March;117(3):431-7.
24. Liesegang TJ. Pigmented conjunctival and scleral lesions. Mayo
Clin Proc 1994 February;69(2):151-61.
25. McDonnell JM, Carpenter JD, Jacobs P, Wan WL, Gilmore JE.
Conjunctival melanocytic lesions in children. Ophthalmology 1989
July;96(7):986-93.
26. Messmer EM, Mackert MJ, Zapp DM, Kampik A. In vivo confocal
microscopy of pigmented conjunctival tumors. Graefes Arch Clin Exp
Ophthalmol 2006 November;244(11):1437-45.
27. Missotten GS, Keijser S, de Keizer RJ, Wolff-Rouendaal D.
Conjunctival melanoma in the Netherlands: a nationwide study. Invest
Ophthalmol Vis Sci 2005 January;46(1):75-82.
28. Pe'er J, Frucht-Pery J. The treatment of primary acquired
melanosis (PAM) with atypia by topical Mitomycin C. Am J Ophthalmol
2005 February;139(2):229-34.
29. Sandinha T, Russell H, Kemp E, Roberts F. Malignant melanoma of
the conjunctiva with intraocular extension: a clinicopathological
study of three cases. Graefes Arch Clin Exp Ophthalmol 2007
March;245(3):431-6.
30. Savar A, Ross MI, Prieto VG, Ivan D, Kim S, Esmaeli B. Sentinel
lymph node biopsy for ocular adnexal melanoma: experience in 30
patients. Ophthalmology 2009 November;116(11):2217-23.
31. Sharara NA, Alexander RA, Luthert PJ, Hungerford JL, Cree IA.
Differential immunoreactivity of melanocytic lesions of the
conjunctiva. Histopathology 2001 October;39(4):426-31.
32. Shields CL, Demirci H, Karatza E, Shields JA. Clinical survey of
1643 melanocytic and nonmelanocytic conjunctival tumors.
Ophthalmology 2004 September;111(9):1747-54.
33. Shields CL, Fasiuddin AF, Mashayekhi A, Shields JA. Conjunctival
nevi: clinical features and natural course in 410 consecutive
patients. Arch Ophthalmol 2004 February;122(2):167-75.
34. Shields CL, Shields JA. Tumors of the conjunctiva and cornea.
Surv Ophthalmol 2004 January;49(1):3-24.
35. Shields CL, Shields JA. Conjunctival tumors in children. Curr
Opin Ophthalmol 2007 September;18(5):351-60.
36. Shields CL, Shields JA, Armstrong T. Management of conjunctival
and corneal melanoma with surgical excision, amniotic membrane
allograft, and topical chemotherapy. Am J Ophthalmol 2001
October;132(4):576-8.
37. Shields JA, Shields CL, De PP. Surgical management of
circumscribed conjunctival melanomas. Ophthal Plast Reconstr Surg
1998 May;14(3):208-15.
38. Shields JA, Shields CL, Luminais S, Eagle RC, Jr. Differentiation
of pigmented conjunctival squamous cell carcinoma from melanoma.
Ophthalmic Surg Lasers Imaging 2003 September;34(5):406-8.
39. Shields JA, Shields CL, Mashayekhi A et al. Primary acquired
melanosis of the conjunctiva: experience with 311 eyes. Trans Am
Ophthalmol Soc 2007;105:61-71; discussion 71-2.:61-71.
40. Shields JA, Shields CL, Mashayekhi A et al. Primary acquired
melanosis of the conjunctiva: risks for progression to melanoma in
311 eyes. The 2006 Lorenz E. Zimmerman lecture. Ophthalmology 2008
March;115(3):511-9.
41. Shildkrot Y, Wilson MW. Conjunctival melanoma: pitfalls and
dilemmas in management. Curr Opin Ophthalmol 2010
September;21(5):380-6.
42. Steuhl KP, Rohrbach JM, Knorr M, Thiel HJ. Significance,
specificity, and ultrastructural localization of HMB-45 antigen in
pigmented ocular tumors. Ophthalmology 1993 February;100(2):208-15.
43. Sugiura M, Colby KA, Mihm MC, Jr., Zembowicz A. Low-risk and
high-risk histologic features in conjunctival primary acquired
melanosis with atypia: Clinicopathologic analysis of 29 cases. Am J
Surg Pathol 2007 February;31(2):185-92.
44. Tatla T, Hungerford J, Plowman N, Ghufoor K, Keene M.
Conjunctival melanoma: the role of conservative surgery and
radiotherapy in regional metastatic disease. Laryngoscope 2005
May;115(5):817-22.
45. Tuomaala S, Aine E, Saari KM, Kivela T. Corneally displaced
malignant conjunctival melanomas. Ophthalmology 2002
May;109(5):914-9.
46. Tuomaala S, Kivela T. Sentinel lymph node biopsy guidelines for
conjunctival melanoma. Melanoma Res 2008 June;18(3):235.
47. Walsh-Conway N, Conway RM. Plaque brachytherapy for the
management of ocular surface malignancies with corneoscleral
invasion. Clin Experiment Ophthalmol 2009 August;37(6):577-83.
48. Wuestemeyer H, Sauerwein W, Meller D et al. Proton radiotherapy
as an alternative to exenteration in the management of extended
conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol 2006
April;244(4):438-46.
Squamous Cell Carcinoma
1. Berenbom A, Milman T, Finger PT. FIT biopsy for conjunctival
squamous cell carcinoma with extensive intraocular invasion. Graefes
Arch Clin Exp Ophthalmol 2008 March;246(3):467-9.
2. Caujolle JP, Maschi C, Chauvel P, Herault J, Gastaud P. [Surgery
and additional protontherapy for treatment of invasive and recurrent
squamous cell carcinomas: technique and preliminary results]. J Fr
Ophtalmol 2009 December;32(10):707-14.
3. Char DH, Crawford JB. Orbital invasion despite topical
anti-metabolite therapy for conjunctival carcinoma. Graefes Arch Clin
Exp Ophthalmol 2008 March;246(3):459-61.
4. Esquenazi S, Fry CL, Holley E. Treatment of biopsy proved
conjunctival intraepithelial neoplasia with topical interferon
alfa-2b. Br J Ophthalmol 2005 September;89(9):1221.
5. Gupta N, Sachdev R, Tandon R. Ocular surface squamous neoplasia in
xeroderma pigmentosum: clinical spectrum and outcome. Graefes Arch
Clin Exp Ophthalmol 2011 April 12.
6. Heindl LM, Hofmann-Rummelt C, Adler W et al. Tumor-associated
lymphangiogenesis in the development of conjunctival squamous cell
carcinoma. Ophthalmology 2010 April;117(4):649-58.
7. Holcombe DJ, Lee GA. Topical interferon alfa-2b for the treatment
of recalcitrant ocular surface squamous neoplasia. Am J Ophthalmol
2006 October;142(4):568-71.
8. Karcioglu ZA, Wagoner MD. Demographics, etiology, and behavior of
conjunctival squamous cell carcinoma in the 21st century.
Ophthalmology 2009 November;116(11):2045-6.
9. Karp CL, Galor A, Chhabra S, Barnes SD, Alfonso EC.
Subconjunctival/perilesional recombinant interferon alpha2b for
ocular surface squamous neoplasia: a 10-year review. Ophthalmology
2010 December;117(12):2241-6.
10. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100
eyes with ocular surface neoplasia. Br J Ophthalmol 2006
July;90(7):819-22.
11. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100
eyes with ocular surface neoplasia. Br J Ophthalmol 2006
July;90(7):819-22.
12. Kim JW, Abramson DH. Topical treatment options for conjunctival
neoplasms. Clin Ophthalmol 2008 September;2(3):503-15.
13. Kim JW, Abramson DH. Topical treatment options for conjunctival
neoplasms. Clin Ophthalmol 2008 September;2(3):503-15.
14. Manderwad GP, Kannabiran C, Honavar SG, Vemuganti GK. Lack of
association of high-risk human papillomavirus in ocular surface
squamous neoplasia in India. Arch Pathol Lab Med 2009
August;133(8):1246-50.
15. Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC. Ocular
surface squamous neoplasia in patients with HIV infection in
sub-Saharan Africa. Curr Opin Oncol 2010 September;22(5):437-42.
16. Parrozzani R, Lazzarini D, Dario A, Midena E. In vivo confocal
microscopy of ocular surface squamous neoplasia. Eye (Lond) 2011
April;25(4):455-60.
17. Parrozzani R, Lazzarini D, emany-Rubio E, Urban F, Midena E.
Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a
long-term safety study. Br J Ophthalmol 2011 March;95(3):355-9.
18. Pe'er J. Ocular surface squamous neoplasia. Ophthalmol Clin North
Am 2005 March;18(1):1-13, vii.
19. Ramonas KM, Conway RM, Daftari IK, Crawford JB, O'Brien JM.
Successful treatment of intraocularly invasive conjunctival squamous
cell carcinoma with proton beam therapy. Arch Ophthalmol 2006
January;124(1):126-8.
20. Rudkin AK, Dodd T, Muecke JS. The differential diagnosis of
localised amelanotic limbal lesions: a review of 162 consecutive
excisions. Br J Ophthalmol 2011 March;95(3):350-4.
21. Rudkin AK, Muecke JS. Adjuvant 5-fluorouracil in the treatment of
localised ocular surface squamous neoplasia. Br J Ophthalmol 2011
January;%20.
22. Sears KS, Rundle PR, Mudhar HS, Rennie IG. The effects of
photodynamic therapy on conjunctival in situ squamous cell
carcinoma--a review of the histopathology. Br J Ophthalmol 2008
May;92(5):716-7.
23. Shields CL, Manchandia A, Subbiah R, Eagle RC, Jr., Shields JA.
Pigmented squamous cell carcinoma in situ of the conjunctiva in 5
cases. Ophthalmology 2008 October;115(10):1673-8.
24. Shields CL, Manchandia A, Subbiah R, Eagle RC, Jr., Shields JA.
Pigmented squamous cell carcinoma in situ of the conjunctiva in 5
cases. Ophthalmology 2008 October;115(10):1673-8.
25. Shields JA, Eagle RC, Marr BP, Shields CL, Grossniklaus HE,
Stulting RD. Invasive spindle cell carcinoma of the conjunctiva
managed by full-thickness eye wall resection. Cornea 2007
September;26(8):1014-6.
26. Verma V, Shen D, Sieving PC, Chan CC. The role of infectious
agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol
2008 July;53(4):312-31.
27. Walsh-Conway N, Conway RM. Plaque brachytherapy for the
management of ocular surface malignancies with corneoscleral
invasion. Clin Experiment Ophthalmol 2009 August;37(6):577-83.
28. Walsh-Conway N, Conway RM. Plaque brachytherapy for the
management of ocular surface malignancies with corneoscleral
invasion. Clin Experiment Ophthalmol 2009 August;37(6):577-83.
Other Conjunctival Tumors
1. Chan CC, Shen D, Mochizuki M et al. Detection of Helicobacter
pylori and Chlamydia pneumoniae genes in primary orbital lymphoma.
Trans Am Ophthalmol Soc 2006;104:62-70.:62-70.
2. Chao AN, Shields CL, Krema H, Shields JA. Outcome of patients with
periocular sebaceous gland carcinoma with and without conjunctival
intraepithelial invasion. Ophthalmology 2001 October;108(10):1877-83.
3. Charlotte F, Doghmi K, Cassoux N et al. Ocular adnexal marginal
zone B cell lymphoma: a clinical and pathologic study of 23 cases.
Virchows Arch 2006 April;448(4):506-16.
4. Coupland SE, Hellmich M, uw-Haedrich C, Lee WR, Stein H.
Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an
assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol 2004
February;242(2):130-45.
5. Coupland SE, White VA, Rootman J, Damato B, Finger PT. A TNM-based
clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab
Med 2009 August;133(8):1262-7.
6. Coupland SE. Ocular adnexal lymphoid tumors: progress in need of
clarification. Am J Ophthalmol 2008 November;146(5):791-2.
7. Esmaeli B, McLaughlin P, Pro B et al. Prospective trial of
targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin)
for front-line treatment of early-stage extranodal indolent ocular
adnexal lymphoma. Ann Oncol 2009 April;20(4):709-14.
8. Farmer JP, Lamba M, Merkur AB et al. Characterization of
lymphoproliferative lesions of the conjunctiva: immunohistochemical
and molecular genetic studies. Can J Ophthalmol 2006
December;41(6):753-60.
9. Ferreri AJ, Dolcetti R, Du MQ et al. Ocular adnexal MALT lymphoma:
an intriguing model for antigen-driven lymphomagenesis and
microbial-targeted therapy. Ann Oncol 2008 May;19(5):835-46.
10. Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G.
Intralesional rituximab: a new therapeutic approach for patients with
conjunctival lymphomas. Ophthalmology 2011 January;118(1):24-8.
11. Ferry JA, Fung CY, Zukerberg L et al. Lymphoma of the ocular
adnexa: A study of 353 cases. Am J Surg Pathol 2007
February;31(2):170-84.
12. Ho VH, Ross MI, Prieto VG, Khaleeq A, Kim S, Esmaeli B. Sentinel
lymph node biopsy for sebaceous cell carcinoma and melanoma of the
ocular adnexa. Arch Otolaryngol Head Neck Surg 2007
August;133(8):820-6.
13. Jakobiec FA. Ocular adnexal lymphoid tumors: progress in need of
clarification. Am J Ophthalmol 2008 June;145(6):941-50.
14. Lagoo AS, Haggerty C, Kim Y et al. Morphologic features of 115
lymphomas of the orbit and ocular adnexa categorized according to the
World Health Organization classification: are marginal zone lymphomas
in the orbit mucosa-associated lymphoid tissue-type lymphomas? Arch
Pathol Lab Med 2008 September;132(9):1405-16.
15. Lee SE, Paik JS, Cho WK et al. Feasibility of the TNM-based
staging system of ocular adnexal extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma). Am J Hematol 2011
March;86(3):262-6.
16. Levecq L, De PP, Jamart J. Conjunctival nevi clinical features
and therapeutic outcomes. Ophthalmology 2010 January;117(1):35-40.
17. Lommatzsch PK, Willerding G, Nenning H, Taubert G. [Inflammatory
juvenile conjunctival nevus (IJCN)]. Klin Monbl Augenheilkd 2007
May;224(5):422-6.
18. Minoda H, Usui N, Sata T, Katano H, Serizawa H, Okada S. Human
herpesvirus-8 in Kaposi's sarcoma of the conjunctiva in a patient
with AIDS. Jpn J Ophthalmol 2006 January;50(1):7-11.
19. Reiser BJ, Mok A, Kukes G, Kim JW. Non-AIDS-related Kaposi
sarcoma involving the tarsal conjunctiva and eyelid margin. Arch
Ophthalmol 2007 June;125(6):838-40.
20. Rishi K, Font RL. Sebaceous gland tumors of the eyelids and
conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of
five cases and literature review. Ophthal Plast Reconstr Surg 2004
January;20(1):31-6.
21. Robinson L, McKellar M, Fitzharris B, Elder M. Topical mitomycin
C for the local treatment of a primary diffuse large B-cell lymphoma
of the palpebral conjunctiva. Clin Experiment Ophthalmol 2009
December;37(9):891-2.
22. Rudkin AK, Muecke JS. Mitomycin-C as adjuvant therapy in the
treatment of sebaceous gland carcinoma in high-risk locations. Clin
Experiment Ophthalmol 2009 May;37(4):352-6.
23. Shields CL, Fasiuddin AF, Mashayekhi A, Shields JA. Conjunctival
nevi: clinical features and natural course in 410 consecutive
patients. Arch Ophthalmol 2004 February;122(2):167-75.
24. Shields CL, Naseripour M, Shields JA, Eagle RC, Jr. Topical
mitomycin-C for pagetoid invasion of the conjunctiva by eyelid
sebaceous gland carcinoma. Ophthalmology 2002
November;109(11):2129-33.
25. Shields CL, Shields JA. Conjunctival tumors in children. Curr
Opin Ophthalmol 2007 September;18(5):351-60.
26. Shields CL, Shields JA. Tumors of the conjunctiva and cornea.
Surv Ophthalmol 2004 January;49(1):3-24.
27. Shields JA, Demirci H, Marr BP, Eagle RC, Jr., Stefanyszyn M,
Shields CL. Conjunctival epithelial involvement by eyelid sebaceous
carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr
Surg 2005 March;21(2):92-6.
28. Sjo LD. Ophthalmic lymphoma: epidemiology and pathogenesis. Acta
Ophthalmol 2009 February;87 Thesis 1:1-20.:1-20.
29. Son SH, Choi BO, Kim GW et al. Primary radiation therapy in
patients with localized orbital marginal zone B-cell lymphoma of
mucosa-associated lymphoid tissue (MALT Lymphoma). Int J Radiat Oncol
Biol Phys 2010 May 1;77(1):86-91.
30. Sullivan TJ, Whitehead K, Williamson R et al. Lymphoproliferative
disease of the ocular adnexa: a clinical and pathologic study with
statistical analysis of 69 patients. Ophthal Plast Reconstr Surg 2005
May;21(3):177-88.
31. Thiagalingam S, Johnson MM, Colby KA, Zembowicz A. Juvenile
conjunctival nevus: clinicopathologic analysis of 33 cases. Am J Surg
Pathol 2008 March;32(3):399-406.
32. Verma V, Shen D, Sieving PC, Chan CC. The role of infectious
agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol
2008 July;53(4):312-31.
XIV.
Low Vision Rehabilitation
Basic Information
1. American Academy of Ophthalmology Preferred Practice Patterns
Committee. Preferred Practice Pattern® Guidelines. Vision
Rehabilitation for Adults. American Academy of Ophthalmology. 2nd
printing 2010. Available at:
http://www.aao.org/ppp.
2. Congdon N, O'Colmain B, Klaver CC, et al.
Causes and prevalence of visual impairment among adults in the
United States. Arch Ophthalmol 2004;122:477-85.
3. Faye EE, Chan-O’Connell, L, Fischer M, Freed B, Pang, L,
Rosenthal B. The Lighthouse Clinican’s Guide to Low Vision
Practice. New York: Lighthouse International; 2011.
Additional Sources
1. Brown GC, Brown MM, Sharma S. Differences between
ophthalmologists’ and patients’ perception of quality of life
associated with macular degeneration. Can J Ophthal 2000;35:127-33.
2. Canadian Journal of Ophthalmology Special Issue on Low Vision
Rehabilitation, June 2006, Ed: Markowitz, SN.
http://pubs.nrc-cnrc.gc.ca/cjo/cho41-03.html.
3. Crane WG, Fletcher DC, Schuchard RA. Prevalence of photopsias and
Charles Bonnet Syndrome in a low vision population. Ophthalmol Clin
North Am 1994;7:143-9.clinic. Br J Ophthalmol 2007;91:296-8.
4. Goodrich GL, Arditi A Low Vision: The Reference – A
bibliographic datavbase that currently contains 11,900 references on
Low Vision. Available at:
www.lvtr.info/
5. Jackson AJ, Wolffsohn JS, Bailey IL. Low Vision Manual.
Philadelphia, Penn:Elsevier, 2007.
6. Markowitz SN, Muller C. Macular perimetry in low vision. Can J
Ophthal 2004;39:56-60.
7. Massof RW, Lidoff L, eds. Issues in Low Vision Rehabilitation.
Service Delivery, policy and Funding. New York: AFB Press, 2001.
8. Mogk LG, Mogk M. Macular Degeneration: The Complete Guide to
Saving and Maximizing Your Sight. New York: Ballantine Books; 2003.
9. Rosenthal BP, Cole RG, London R. Functional Assessment of Low
Vision. St. Louis, MO: Mosby, 1996.
10. Faye E.E.: Clinical low vision (2nd. ed.). Boston; Little, Brown,
1984
11. Visual disturbances and blindness (H53-H54), In: International
Statistical Classification of Diseases and Related Health Problems.
WHO, 10th Revision, Version for 2007. See on-line:
http://apps.who.int/classifications/apps/icd/icd10online/
Additional Papers (after 2000)
1. Biousse V, Skibell BC, Watts RL, et al. Ophthalmologic features of
Parkinson's disease. Neurology 2004;62:177-80.
2. de Boer MR, Pluijm SM, Lips P, et al. Different
aspects of visual impairment as risk factors for falls and fractures
in older men and women. J Bone Miner Res 2004;19:1539-47.
3. Dandona L, Dandona R.
Revision of visual impairment definitions in the International
Statistical Classification of Diseases. BMC Med. 2006 Mar 16;4:7.
4. Dhital A, Pey T, Stanford MR. Visual loss and falls: a review. Eye
(Lond). 2010 24(9):1437-46
5. Gogate P, Rishikeshi N, Mehata R, Ranade S, Kharat J, Deshpande M.
Visual impairment in the hearing impaired students. Indian J
Ophthalmol. 2009 Nov-Dec;57(6):451-3.
6. Hassell JB, Lamoureux EL, Keeffe JE. Impact
of age related macular degeneration on quality of life. Br J
Ophthalmol 2006; 90: 593-596
7. Horowitz A. Vision impairment and functional disability among
nursing home residents. Gerontologist 1994;34:316-23.
8. Jackson ML, Bassett K, Nirmalan PV, Sayre EC. Contrast sensitivity
and visual hallucinations in patients referred to a low vision
rehabilitation. Br J Ophthalmol 2007;91:296-298.
9. Johnson L, Buckley JG, Scally AJ, Elliott DB. Multifocal
spectacles increase variability in toe clearance and risk of tripping
in the elderly. Invest Ophthalmol Vis Sci 2007;48:1466-71.
10. Lee PP, Spritzer K, Hays RD. The impact of blurred vision on
functioning and well being. Ophthalmology 1997;104:390-6.
11. Lord SR, Dayhew J, Howland A. Multifocal glasses impair
edge-contrast sensitivity and depth perception and increase the risk
of falls in older people. J Am Geriatr Soc 2002;50:1760-6.
12. Owsley C, Sloane ME. Contrast sensitivity, acuity, and the
perception of 'real-world' targets. Br J Ophthalmol 1987;71:791-6.
13. Pollard TL, Simpson JA, Lamoureux EL, Keeffe JE. Barriers to
accessing low vision services. Ophthalmic Physiol Opt 2003;23:321-7.
14. Riordan-Eva P, Cunningham E (Eds). Vaughan & Asbury's General
Ophthalmology, Lange Clinical Medicine
15. Scott IU, Smiddy WE, Schiffman J, et al.
Quality of life of low-vision patients and the impact of
low-vision services. Am J Ophthalmol 1999;128:54-62.
16. Shaaban S, El-Lakkany AR, Swelam A, Anwar G.
Low vision AIDS provision for visually impaired egyptian patients - a
clinical outcome. Middle East Afr J Ophthalmol. 2009
Jan;16(1):29-34.
17. Stelmack JA, Rosenbloom AA, Brenneman CS, Stelmack TR. Patients'
perceptions of the need for low vision devices. J Vis Impair Blind
2003;97:521-35.
18. Stelmack JA, Tang SC, Reda DF et al. Outcomes of the Veterans
Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol
2008;126:608-17.
19. Trauzettel-Klosinski, S. Rehabilitation for visual disorders. J
Neuro-Ophthalmol 2010; 30: 73-84
20. Wang JJ, Mitchell P, Smith W, Leeder SR. Factors associated with
use of community support services in an older Australian population.
Aust N Z J Public Health 1999;23:147-53.
21. Warren, M. Barstow, B. Occupational Therapy interventions for
Adults with Low Vision. AOTA Press. 2010
22. West SK, Munoz B, Rubin GS, et al. Function and visual impairment
in a population-based study of older adults. The SEE project.
Salisbury Eye Evaluation. Invest Ophthalmol Vis Sci 1997;38:72-82.
23. West SK, Rubin GS, Broman AT, et al. How does visual impairment
affect performance on tasks of everyday life? The SEE Project.
Salisbury Eye Evaluation. Arch Ophthalmol 2002;120:774-80.
24. Wolter M, Preda S. Visual deficits following stroke: maximizing
participation in rehabilitation. Top Stroke Rehabil 2006;13:12-21.
XV. Ethics
and Professionalism in Ophthalmology
Medical Ethics Documents
1. The Hippocratic Oath
http://www.nlm.nih.gov/hmd/greek/greek_oath.html
2. WMA Declaration of Geneva
http://www.wma.net/en/30publications/10policies/g1/
3. Ethical Code, International Council of Ophthalmology
www.icoph.org/pdf/icoethicalcode.pdf
4. Code of Ethics, American Academy of Ophthalmology
5. Nuremburg Code
http://ohsr.od.nih.gov/guidelines/nuremberg.html
6. WMA Declaration of Helsinki
http://www.wma.net/en/30publications/10policies/b3/
7. Belmont Report
Suggested Additional Reading
1. Angell, M. The Truth About Drug Companies, How They Deceive Us and
What to Do About It. New York, Random House, 2005
2. Gawande A. Better: A Surgeon's Notes on Performance. New York.
Metropolitan Books, 2010
3. Harbin T. Waking up Blind - Lawsuits Over Eye Surgery.
Minneapolis, Langdon Street Press 2009
4. Kassirer J. On The Take: How Medicine’s Complicity With Big
Business Can Endanger Your Health. New York, Oxford University Press,
2004
XVI. Community
Eye Health
1.
Johnson G (editor). The
epidemiology of eye disease. Third edition. Arnold. 2011.
2.
World Health
Organization: Action plan for the prevention of avoidable blindness and visual
impairment 2009–2013. [Available from: http://www.who.int/entity/blindness/ACTION_PLAN_WHA62-1-English.pdf]
4.
World Sight Day report 2013: towards
universal eye health. International Agency for the Prevention of Blindness,
2013.
5.
Stevens GA, White RA, Flaxman SR et
al. Global prevalence of visual impairment and blindness – Magnitude and
temporal trends 1990-2010. Ophthalmology 2013; 120: 2377-2384.
6.
Pascolini SD, Mariotti SP. Global
estimates of visual impairment: Br J Ophthalmol 2012;96: 614-618.
9. Inclusion Made Easy in Eye Health Programs.
[Available from: cbm.org/disability-inclusive-eye-health]
10. Facing up to Disability. Community Eye
Health Journal, Volume 26, Issue 81, 2013. [Available from: http://www.cehjournal.org/wp-content/uploads/facing-up-to-disability.pdf]
11. The Economic Costs of
Exclusion and Gains of Inclusion of People with Disabilities. Evidence from Low
and Middle Income Countries. Lena Morgan Banks and Sarah Polock. [Available
from: http://www.iapb.org/sites/iapb.org/files/CBM_Costs%20of%20Exclusion%20and%20Gains%20of%20Inclusion%20Report_2015.pdf]
For more references, Sections I-X click here, use the sidebar menu to select 17.2 Appendix: References Sections I-X, or click on Newer Post below.
